{"id":"norpace","rwe":[],"_fda":{"id":"82d9eecb-bbb9-4daf-863e-362ab0cbadaf","set_id":"11a68e26-d2e4-48f6-ba0f-9bdd5778f25a","openfda":{"upc":["0300933129015","0300933127011"],"unii":["N6BOM1935W"],"route":["ORAL"],"rxcui":["309958","309960"],"spl_id":["82d9eecb-bbb9-4daf-863e-362ab0cbadaf"],"brand_name":["Disopyramide Phosphate"],"spl_set_id":["11a68e26-d2e4-48f6-ba0f-9bdd5778f25a"],"package_ndc":["0093-3127-01","0093-3129-01"],"product_ndc":["0093-3127","0093-3129"],"generic_name":["DISOPYRAMIDE PHOSPHATE"],"product_type":["HUMAN PRESCRIPTION DRUG"],"substance_name":["DISOPYRAMIDE PHOSPHATE"],"manufacturer_name":["Teva Pharmaceuticals USA, Inc."],"application_number":["ANDA070101","ANDA070102"],"is_original_packager":[true]},"version":"16","warnings":["WARNINGS Mortality In the National Heart, Lung and Blood Institute’s Cardiac Arrhythmia Suppression Trial (CAST), a long-term, multi-center, randomized, double-blind study in patients with asymptomatic non-life-threatening ventricular arrhythmias who had had a myocardial infarction more than 6 days but less than 2 years previously, an excessive mortality or non-fatal cardiac arrest rate (7.7%) was seen in patients treated with encainide or flecainide compared with that seen in patients assigned to carefully matched placebo-treated groups (3.0%). The average duration of treatment with encainide or flecainide in this study was 10 months. The applicability of the CAST results to other populations (e.g., those without recent myocardial infarction) is uncertain. Considering the known proarrhythmic properties of disopyramide phosphate and the lack of evidence of improved survival for any antiarrhythmic drug in patients without life-threatening arrhythmias, the use of disopyramide phosphate as well as other antiarrhythmic agents should be reserved for patients with life-threatening ventricular arrhythmias. Negative Inotropic Properties Heart Failure/Hypotension Disopyramide phosphate may cause or worsen congestive heart failure or produce severe hypotension as a consequence of its negative inotropic properties. Hypotension has been observed primarily in patients with primary cardiomyopathy or inadequately compensated congestive heart failure. Disopyramide phosphate should not be used in patients with uncompensated or marginally compensated congestive heart failure or hypotension unless the congestive heart failure or hypotension is secondary to cardiac arrhythmia. Patients with a history of heart failure may be treated with disopyramide phosphate, but careful attention must be given to the maintenance of cardiac function, including optimal digitalization. If hypotension occurs or congestive heart failure worsens, disopyramide phosphate should be discontinued and, if necessary, restarted at a lower dosage only after adequate cardiac compensation has been established. QRS Widening Although it is unusual, significant widening (greater than 25%) of the QRS complex may occur during disopyramide phosphate administration; in such cases disopyramide phosphate should be discontinued. Q-T Prolongation As with other Type 1 antiarrhythmic drugs, prolongation of the Q-T interval (corrected) and worsening of the arrhythmia, including ventricular tachycardia and ventricular fibrillation, may occur. Patients who have evidenced prolongation of the Q-T interval in response to quinidine may be at particular risk. As with other Type 1A antiarrhythmics, disopyramide phosphate has been associated with torsade de pointes. If a Q-T prolongation of greater than 25% is observed and if ectopy continues, the patient should be monitored closely, and consideration given to discontinuing disopyramide phosphate. Hypoglycemia In rare instances significant lowering of blood-glucose values has been reported during disopyramide phosphate administration. The physician should be alert to this possibility, especially in patients with congestive heart failure, chronic malnutrition, hepatic, renal or other diseases, or drugs (e.g., beta-adrenoceptor blockers, alcohol) which could compromise preservation of the normal glucoregulatory mechanisms in the absence of food. In these patients, the blood-glucose levels should be carefully followed. Concomitant Antiarrhythmic Therapy The concomitant use of disopyramide phosphate with other Type 1A antiarrhythmic agents (such as quinidine or procainamide), Type 1C antiarrhythmics (such as encainide, flecainide or propafenone), and/or propranolol should be reserved for patients with life-threatening arrhythmias who are demonstrably unresponsive to single-agent antiarrhythmic therapy. Such use may produce serious negative inotropic effects, or may excessively prolong conduction. This should be considered particularly in patients with any degree of cardiac decompensation or those with a prior history thereof. Patients receiving more than one antiarrhythmic drug must be carefully monitored. Heart Block If first-degree heart block develops in a patient receiving disopyramide phosphate, the dosage should be reduced. If the block persists despite reduction of dosage, continuation of the drug must depend upon weighing the benefit being obtained against the risk of higher degrees of heart block. Development of second- or third-degree AV block or unifascicular, bifascicular, or trifascicular block requires discontinuation of disopyramide phosphate therapy, unless the ventricular rate is adequately controlled by a temporary or implanted ventricular pacemaker. Anticholinergic Activity Because of its anticholinergic activity, disopyramide phosphate should not be used in patients with glaucoma, myasthenia gravis or urinary retention unless adequate overriding measures are taken; these consist of the topical application of potent miotics (e.g., pilocarpine) for patients with glaucoma, and catheter drainage or operative relief for patients with urinary retention. Urinary retention may occur in patients of either sex as a consequence of disopyramide phosphate administration, but males with benign prostatic hypertrophy are at particular risk. In patients with a family history of glaucoma, intraocular pressure should be measured before initiating disopyramide phosphate therapy. Disopyramide phosphate should be used with special care in patients with myasthenia gravis since its anticholinergic properties could precipitate a myasthenic crisis in such patients."],"pregnancy":["Pregnancy Teratogenic Effects Disopyramide phosphate was associated with decreased numbers of implantation sites and decreased growth and survival of pups when administered to pregnant rats at 250 mg/kg/day (20 or more times the usual daily human dose of 12 mg/kg, assuming a patient weight of at least 50 kg), a level at which weight gain and food consumption of dams were also reduced. Increased resorption rates were reported in rabbits at 60 mg/kg/day (5 or more times the usual daily human dose). Effects on implantation, pup growth, and survival were not evaluated in rabbits. There are no adequate and well-controlled studies in pregnant women. Disopyramide phosphate should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Nonteratogenic Effects Disopyramide phosphate has been reported to stimulate contractions of the pregnant uterus. Disopyramide has been found in human fetal blood."],"overdosage":["OVERDOSAGE Symptoms Deliberate or accidental overdosage of oral disopyramide may be followed by apnea, loss of consciousness, cardiac arrhythmias, and loss of spontaneous respiration. Death has occurred following overdosage. Toxic plasma levels of disopyramide produce excessive widening of the QRS complex and Q-T interval, worsening of congestive heart failure, hypotension, varying kinds and degrees of conduction disturbance, bradycardia, and finally asystole. Obvious anticholinergic effects are also observed. The approximate oral LD 50 of disopyramide phosphate is 580 and 700 mg/kg for rats and mice, respectively. Treatment Experience indicates that prompt and vigorous treatment of overdosage is necessary, even in the absence of symptoms. Such treatment may be life-saving. No specific antidote for disopyramide phosphate has been identified. Treatment should be symptomatic and may include induction of emesis or gastric lavage, administration of a cathartic followed by activated charcoal by mouth or stomach tube, intravenous administration of isoproterenol and dopamine, insertion of an intra-aortic balloon for counterpulsation, and mechanically assisted ventilation. Hemodialysis or, preferably, hemoperfusion with charcoal may be employed to lower serum concentration of the drug. The electrocardiogram should be monitored, and supportive therapy with cardiac glycosides and diuretics should be given as required. If progressive AV block should develop, endocardial pacing should be implemented. In case of any impaired renal function, measures to increase the glomerular filtration rate may reduce the toxicity (disopyramide is excreted primarily by the kidney). The anticholinergic effects can be reversed with neostigmine at the discretion of the physician. Altering the urinary pH in humans does not affect the plasma half-life or the amount of disopyramide excreted in the urine."],"description":["DESCRIPTION Disopyramide phosphate, USP is an antiarrhythmic drug available for oral administration in capsules containing 100 mg or 150 mg of disopyramide base, present as the phosphate. The base content of the phosphate salt is 77.6%. The structural formula of disopyramide phosphate, USP is: C 21 H 29 N 3 O•H 3 PO 4 M.W. 437.47 α-[2-(diisopropylamino) ethyl]-α-phenyl-2-pyridineacetamide phosphate Disopyramide phosphate, USP is freely soluble in water, and the free base (pKa 10.4) has an aqueous solubility of 1 mg/mL. The chloroform:water partition coefficient of the base is 3.1 at pH 7.2. Disopyramide phosphate, USP is a racemic mixture of d - and l -isomers. This drug is not chemically related to other antiarrhythmic drugs. Inactive Ingredients: lactose monohydrate, magnesium stearate and sodium starch glycolate. Capsule shell and ink ingredients: black iron oxide, D&C Red #28, D&C Red #33, D&C Yellow #10, FD&C Blue #1, gelatin, propylene glycol, shellac, sodium lauryl sulfate and titanium dioxide. 1"],"precautions":["PRECAUTIONS General Atrial Tachyarrhythmias Patients with atrial flutter or fibrillation should be digitalized prior to disopyramide phosphate administration to ensure that drug-induced enhancement of AV conduction does not result in an increase of ventricular rate beyond physiologically acceptable limits. Conduction Abnormalities Care should be taken when prescribing disopyramide phosphate for patients with sick sinus syndrome (bradycardia-tachycardia syndrome), Wolff-Parkinson-White syndrome (WPW), or bundle branch block. The effect of disopyramide phosphate in these conditions is uncertain at present. Cardiomyopathy Patients with myocarditis or other cardiomyopathy may develop significant hypotension in response to the usual dosage of disopyramide phosphate, probably due to cardiodepressant mechanisms. Therefore, a loading dose of disopyramide phosphate should not be given to such patients, and initial dosage and subsequent dosage adjustments should be made under close supervision (see DOSAGE AND ADMINISTRATION ). Renal Impairment More than 50% of disopyramide is excreted in the urine unchanged. Therefore disopyramide phosphate dosage should be reduced in patients with impaired renal function (see DOSAGE AND ADMINISTRATION ). The electrocardiogram should be carefully monitored for prolongation of PR interval, evidence of QRS widening, or other signs of overdosage (see OVERDOSAGE ). Hepatic Impairment Hepatic impairment also causes an increase in the plasma half-life of disopyramide. Dosage should be reduced for patients with such impairment. The electrocardiogram should be carefully monitored for signs of overdosage (see OVERDOSAGE ). Patients with cardiac dysfunction have a higher potential for hepatic impairment; this should be considered when administering disopyramide phosphate. Potassium Imbalance Antiarrhythmic drugs may be ineffective in patients with hypokalemia, and their toxic effects may be enhanced in patients with hyperkalemia. Therefore, potassium abnormalities should be corrected before starting disopyramide phosphate therapy. Drug Interactions If phenytoin or other hepatic enzyme inducers are taken concurrently with disopyramide phosphate, lower plasma levels of disopyramide may occur. Monitoring of disopyramide plasma levels is recommended in such concurrent use to avoid ineffective therapy. Other antiarrhythmic drugs (e.g., quinidine, procainamide, lidocaine, propranolol) have occasionally been used concurrently with disopyramide phosphate. Excessive widening of the QRS complex and/or prolongation of the Q-T interval may occur in these situations (see WARNINGS ). In healthy subjects, no significant drug-drug interaction was observed when disopyramide phosphate was coadministered with either propranolol or diazepam. Concomitant administration of disopyramide phosphate and quinidine resulted in slight increases in plasma disopyramide levels and slight decreases in plasma quinidine levels. disopyramide phosphate does not increase serum digoxin levels. Until data on possible interactions between verapamil and disopyramide phosphate are obtained, disopyramide should not be administered within 48 hours before or 24 hours after verapamil administration. Although potent inhibitors of cytochrome P450 3A4 (e.g., ketoconazole) have not been studied clinically, in vitro studies have shown that erythromycin and oleandomycin inhibit the metabolism of disopyramide. Cases of life-threatening interactions have been reported for disopyramide when given with clarithromycin and erythromycin indicating that coadministration of disopyramide with inhibitors of cytochrome P450 3A4 could result in potentially fatal interaction. Carcinogenesis, Mutagenesis, Impairment of Fertility Eighteen months of disopyramide phosphate administration to rats, at oral doses up to 400 mg/kg/day (about 30 times the usual daily human dose of 600 mg/day, assuming a patient weight of at least 50 kg), revealed no evidence of carcinogenic potential. An evaluation of mutagenic potential by Ames test was negative. disopyramide phosphate, at doses up to 250 mg/kg/day, did not adversely affect fertility of rats. Pregnancy Teratogenic Effects Disopyramide phosphate was associated with decreased numbers of implantation sites and decreased growth and survival of pups when administered to pregnant rats at 250 mg/kg/day (20 or more times the usual daily human dose of 12 mg/kg, assuming a patient weight of at least 50 kg), a level at which weight gain and food consumption of dams were also reduced. Increased resorption rates were reported in rabbits at 60 mg/kg/day (5 or more times the usual daily human dose). Effects on implantation, pup growth, and survival were not evaluated in rabbits. There are no adequate and well-controlled studies in pregnant women. Disopyramide phosphate should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Nonteratogenic Effects Disopyramide phosphate has been reported to stimulate contractions of the pregnant uterus. Disopyramide has been found in human fetal blood. Labor and Delivery It is not known whether the use of disopyramide phosphate during labor or delivery has immediate or delayed adverse effects on the fetus, or whether it prolongs the duration of labor or increases the need for forceps delivery or other obstetric intervention. Nursing Mothers Studies in rats have shown that the concentration of disopyramide and its metabolites is between one and three times greater in milk than it is in plasma. Following oral administration, disopyramide has been detected in human milk at a concentration not exceeding that in plasma. Because of the potential for serious adverse reactions in nursing infants from disopyramide phosphate, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother. Pediatric Use Safety and effectiveness in pediatric patients have not been established (see DOSAGE AND ADMINISTRATION ). Geriatric Use Clinical studies of disopyramide phosphate did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy. Because of its anticholinergic activity, disopyramide phosphate should not be used in patients with glaucoma, urinary retention, or benign prostatic hypertrophy (medical conditions commonly associated with the elderly) unless adequate overriding measures are taken (see WARNINGS: Anticholinergic Activity ). In the event of increased anticholinergic side effects, plasma levels of disopyramide should be monitored and the dose of the drug adjusted accordingly. A reduction of the dose by one third, from the recommended 600 mg/day to 400 mg/day, would be reasonable, without changing the dosing interval. This drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function (see PRECAUTIONS : Renal Impairment and DOSAGE AND ADMINISTRATION )."],"how_supplied":["HOW SUPPLIED Disopyramide phosphate capsules, USP are supplied as: 100 mg - hard gelatin capsule with a light-blue body imprinted “93-3127” and a scarlet cap imprinted “93-3127”, containing 100 mg of disopyramide base present as the phosphate, in bottles of 100 (NDC 0093-3127-01). 150 mg - hard gelatin capsule with a scarlet body imprinted “93-3129” and a buff cap imprinted “93-3129”, containing 150 mg of disopyramide base present as the phosphate, in bottles of 100 (NDC 0093-3129-01). Storage Store at 20° to 25°C (68° to 77°F) [See USP Controlled Room Temperature]. Dispense in a tight, light-resistant container as defined in the USP, with a child-resistant closure (as required). Keep this and all medications out of the reach of children. Manufactured In Croatia By: Pliva Hrvatska d.o.o. Zagreb, Croatia Manufactured For: Teva Pharmaceuticals Parsippany, NJ 07054 Rev. A 9/2024"],"geriatric_use":["Geriatric Use Clinical studies of disopyramide phosphate did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy. Because of its anticholinergic activity, disopyramide phosphate should not be used in patients with glaucoma, urinary retention, or benign prostatic hypertrophy (medical conditions commonly associated with the elderly) unless adequate overriding measures are taken (see WARNINGS: Anticholinergic Activity ). In the event of increased anticholinergic side effects, plasma levels of disopyramide should be monitored and the dose of the drug adjusted accordingly. A reduction of the dose by one third, from the recommended 600 mg/day to 400 mg/day, would be reasonable, without changing the dosing interval. This drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function (see PRECAUTIONS : Renal Impairment and DOSAGE AND ADMINISTRATION )."],"pediatric_use":["Pediatric Use Safety and effectiveness in pediatric patients have not been established (see DOSAGE AND ADMINISTRATION )."],"effective_time":"20240925","warnings_table":["
MortalityIn the National Heart, Lung and Blood Institute’s Cardiac Arrhythmia Suppression Trial (CAST), a long-term, multi-center, randomized, double-blind study in patients with asymptomatic non-life-threatening ventricular arrhythmias who had had a myocardial infarction more than 6 days but less than 2 years previously, an excessive mortality or non-fatal cardiac arrest rate (7.7%) was seen in patients treated with encainide or flecainide compared with that seen in patients assigned to carefully matched placebo-treated groups (3.0%). The average duration of treatment with encainide or flecainide in this study was 10 months.The applicability of the CAST results to other populations (e.g., those without recent myocardial infarction) is uncertain. Considering the known proarrhythmic properties of disopyramide phosphate and the lack of evidence of improved survival for any antiarrhythmic drug in patients without life-threatening arrhythmias, the use of disopyramide phosphate as well as other antiarrhythmic agents should be reserved for patients with life-threatening ventricular arrhythmias.
"],"nursing_mothers":["Nursing Mothers Studies in rats have shown that the concentration of disopyramide and its metabolites is between one and three times greater in milk than it is in plasma. Following oral administration, disopyramide has been detected in human milk at a concentration not exceeding that in plasma. Because of the potential for serious adverse reactions in nursing infants from disopyramide phosphate, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother."],"adverse_reactions":["ADVERSE REACTIONS The adverse reactions which were reported in disopyramide phosphate clinical trials encompass observations in 1,500 patients, including 90 patients studied for at least 4 years. The most serious adverse reactions are hypotension and congestive heart failure. The most common adverse reactions, which are dose dependent, are associated with the anticholinergic properties of the drug. These may be transitory, but may be persistent or can be severe. Urinary retention is the most serious anticholinergic effect. The following reactions were reported in 10% to 40% of patients: Anticholinergic: dry mouth (32%), urinary hesitancy (14%), constipation (11%) The following reactions were reported in 3% to 9% of patients: Anticholinergic: blurred vision, dry nose/eyes/throat Genitourinary: urinary retention, urinary frequency and urgency Gastrointestinal: nausea, pain/bloating/gas General: dizziness, general fatigue/muscle weakness, headache, malaise, aches/pains The following reactions were reported in 1% to 3% of patients: Genitourinary: impotence Cardiovascular: hypotension with or without congestive heart failure, increased congestive heart failure (see WARNINGS ), cardiac conduction disturbances (see WARNINGS ), edema/weight gain, shortness of breath, syncope, chest pain Gastrointestinal: anorexia, diarrhea, vomiting Dermatologic: generalized rash/dermatoses, itching Central nervous system: nervousness Other: hypokalemia, elevated cholesterol/triglycerides The following reactions were reported in less than 1%: Depression, insomnia, dysuria, numbness/tingling, elevated liver enzymes, AV block, elevated BUN, elevated creatinine, decreased hemoglobin/hematocrit Hypoglycemia has been reported in association with disopyramide phosphate administration (see WARNINGS ). Infrequent occurrences of reversible cholestatic jaundice, fever, and respiratory difficulty have been reported in association with disopyramide therapy, as have rare instances of thrombocytopenia, reversible agranulocytosis, and gynecomastia. Some cases of LE (lupus erythematosus) symptoms have been reported; most cases occurred in patients who had been switched to disopyramide from procainamide following the development of LE symptoms. Rarely, acute psychosis has been reported following disopyramide phosphate therapy, with prompt return to normal mental status when therapy was stopped. The physician should be aware of these possible reactions and should discontinue disopyramide phosphate therapy promptly if they occur. To report SUSPECTED ADVERSE REACTIONS, contact Teva at 1-888-838-2872 or FDA at 1-800-FDA-1088 or http://www.fda.gov/ for voluntary reporting of adverse reactions."],"contraindications":["CONTRAINDICATIONS Disopyramide phosphate is contraindicated in the presence of cardiogenic shock, preexisting second- or third-degree AV block (if no pacemaker is present), congenital Q-T prolongation, or known hypersensitivity to the drug."],"drug_interactions":["Drug Interactions If phenytoin or other hepatic enzyme inducers are taken concurrently with disopyramide phosphate, lower plasma levels of disopyramide may occur. Monitoring of disopyramide plasma levels is recommended in such concurrent use to avoid ineffective therapy. Other antiarrhythmic drugs (e.g., quinidine, procainamide, lidocaine, propranolol) have occasionally been used concurrently with disopyramide phosphate. Excessive widening of the QRS complex and/or prolongation of the Q-T interval may occur in these situations (see WARNINGS ). In healthy subjects, no significant drug-drug interaction was observed when disopyramide phosphate was coadministered with either propranolol or diazepam. Concomitant administration of disopyramide phosphate and quinidine resulted in slight increases in plasma disopyramide levels and slight decreases in plasma quinidine levels. disopyramide phosphate does not increase serum digoxin levels. Until data on possible interactions between verapamil and disopyramide phosphate are obtained, disopyramide should not be administered within 48 hours before or 24 hours after verapamil administration. Although potent inhibitors of cytochrome P450 3A4 (e.g., ketoconazole) have not been studied clinically, in vitro studies have shown that erythromycin and oleandomycin inhibit the metabolism of disopyramide. Cases of life-threatening interactions have been reported for disopyramide when given with clarithromycin and erythromycin indicating that coadministration of disopyramide with inhibitors of cytochrome P450 3A4 could result in potentially fatal interaction."],"labor_and_delivery":["Labor and Delivery It is not known whether the use of disopyramide phosphate during labor or delivery has immediate or delayed adverse effects on the fetus, or whether it prolongs the duration of labor or increases the need for forceps delivery or other obstetric intervention."],"general_precautions":["General Atrial Tachyarrhythmias Patients with atrial flutter or fibrillation should be digitalized prior to disopyramide phosphate administration to ensure that drug-induced enhancement of AV conduction does not result in an increase of ventricular rate beyond physiologically acceptable limits. Conduction Abnormalities Care should be taken when prescribing disopyramide phosphate for patients with sick sinus syndrome (bradycardia-tachycardia syndrome), Wolff-Parkinson-White syndrome (WPW), or bundle branch block. The effect of disopyramide phosphate in these conditions is uncertain at present. Cardiomyopathy Patients with myocarditis or other cardiomyopathy may develop significant hypotension in response to the usual dosage of disopyramide phosphate, probably due to cardiodepressant mechanisms. Therefore, a loading dose of disopyramide phosphate should not be given to such patients, and initial dosage and subsequent dosage adjustments should be made under close supervision (see DOSAGE AND ADMINISTRATION ). Renal Impairment More than 50% of disopyramide is excreted in the urine unchanged. Therefore disopyramide phosphate dosage should be reduced in patients with impaired renal function (see DOSAGE AND ADMINISTRATION ). The electrocardiogram should be carefully monitored for prolongation of PR interval, evidence of QRS widening, or other signs of overdosage (see OVERDOSAGE ). Hepatic Impairment Hepatic impairment also causes an increase in the plasma half-life of disopyramide. Dosage should be reduced for patients with such impairment. The electrocardiogram should be carefully monitored for signs of overdosage (see OVERDOSAGE ). Patients with cardiac dysfunction have a higher potential for hepatic impairment; this should be considered when administering disopyramide phosphate. Potassium Imbalance Antiarrhythmic drugs may be ineffective in patients with hypokalemia, and their toxic effects may be enhanced in patients with hyperkalemia. Therefore, potassium abnormalities should be corrected before starting disopyramide phosphate therapy."],"clinical_pharmacology":["CLINICAL PHARMACOLOGY Mechanisms of Action Disopyramide phosphate is a Type 1 antiarrhythmic drug (i.e., similar to procainamide and quinidine). In animal studies, disopyramide phosphate decreases the rate of diastolic depolarization (phase 4) in cells with augmented automaticity, decreases the upstroke velocity (phase 0) and increases the action potential duration of normal cardiac cells, decreases the disparity in refractoriness between infarcted and adjacent normally perfused myocardium, and has no effect on alpha- or beta-adrenergic receptors. Electrophysiology In man, disopyramide phosphate at therapeutic plasma levels shortens the sinus node recovery time, lengthens the effective refractory period of the atrium, and has a minimal effect on the effective refractory period of the AV node. Little effect has been shown on AV-nodal and His-Purkinje conduction times or QRS duration. However, prolongation of conduction in accessory pathways occurs. Hemodynamics At recommended oral doses, disopyramide phosphate rarely produces significant alterations of blood pressure in patients without congestive heart failure (see WARNINGS ). With intravenous disopyramide phosphate, either increases in systolic/diastolic or decreases in systolic blood pressure have been reported, depending on the infusion rate and the patient population. Intravenous disopyramide phosphate may cause cardiac depression with an approximate mean 10% reduction of cardiac output, which is more pronounced in patients with cardiac dysfunction. Anticholinergic Activity The in vitro anticholinergic activity of disopyramide phosphate is approximately 0.06% that of atropine; however, the usual dose for disopyramide phosphate is 150 mg every 6 hours compared to 0.4 to 0.6 mg for atropine (see WARNINGS and ADVERSE REACTIONS for anticholinergic side effects). Pharmacokinetics Following oral administration of disopyramide phosphate, disopyramide phosphate is rapidly and almost completely absorbed, and peak plasma levels are usually attained within 2 hours. The usual therapeutic plasma levels of disopyramide base are 2 to 4 mcg/mL, and at these concentrations protein binding varies from 50% to 65%. Because of concentration-dependent protein binding, it is difficult to predict the concentration of the free drug when total drug is measured. The mean plasma half-life of disopyramide in healthy humans is 6.7 hours (range of 4 to 10 hours). In six patients with impaired renal function (creatinine clearance less than 40 mL/min), disopyramide half-life values were 8 to 18 hours. After the oral administration of 200 mg of disopyramide to 10 cardiac patients with borderline to moderate heart failure, the time to peak serum concentration of 2.3 ± 1.5 hours (mean ± SD) was increased, and the mean peak serum concentration of 4.8 ± 1.6 mcg/mL was higher than in healthy volunteers. After intravenous administration in these same patients, the mean elimination half-life was 9.7 ± 4.2 hours (range in healthy volunteers of 4.4 to 7.8 hours). In a second study of the oral administration of disopyramide to 7 patients with heart disease, including left ventricular dysfunction, the mean plasma half-life was slightly prolonged to 7.8 ± 1.9 hours (range of 5 to 9.5 hours). In healthy men, about 50% of a given dose of disopyramide is excreted in the urine as the unchanged drug, about 20% as the mono-N-dealkylated metabolite, and 10% as the other metabolites. The plasma concentration of the major metabolite is approximately one tenth that of disopyramide. Altering the urinary pH in man does not affect the plasma half-life of disopyramide. Drug Interactions Effects of other drugs on disopyramide pharmacokinetics: In vitro metabolic studies indicated that disopyramide is metabolized by cytochrome P450 3A4 and that inhibitors of this enzyme may result in elevation of plasma levels of disopyramide. Although specific drug interaction studies have not been done, cases of life-threatening interactions have been reported for disopyramide when given with clarithromycin and erythromycin."],"indications_and_usage":["INDICATIONS AND USAGE Disopyramide phosphate is indicated for the treatment of documented ventricular arrhythmias such as sustained ventricular tachycardia, that, in the judgment of the physician, are life-threatening. Because of the proarrhythmic effects of disopyramide phosphate, its use with lesser arrhythmias is generally not recommended. Treatment of patients with asymptomatic ventricular premature contractions should be avoided. Initiation of disopyramide phosphate treatment, as with other antiarrhythmic agents used to treat life-threatening arrhythmias, should be carried out in the hospital. Antiarrhythmic drugs have not been shown to enhance survival in patients with ventricular arrhythmias."],"dosage_and_administration":["DOSAGE AND ADMINISTRATION The dosage of disopyramide phosphate capsules must be individualized for each patient on the basis of response and tolerance. The usual adult dosage of disopyramide phosphate capsules is 400 to 800 mg per day given in divided doses. The recommended dosage for most adults is 600 mg/day given in divided doses (150 mg every 6 hours). For patients whose body weight is less than 110 pounds (50 kg), the recommended dosage is 400 mg/day given in divided doses (100 mg every 6 hours). In the event of increased anticholinergic side effects, plasma levels of disopyramide should be monitored and the dose of the drug adjusted accordingly. A reduction of the dose by one third, from the recommended 600 mg/day to 400 mg/day, would be reasonable, without changing the dosing interval. For patients with cardiomyopathy or possible cardiac decompensation, a loading dose, as discussed below, should not be given, and initial dosage should be limited to 100 mg every 6 to 8 hours. Subsequent dosage adjustments should be made gradually, with close monitoring for the possible development of hypotension and/or congestive heart failure (see WARNINGS ). For patients with moderate renal insufficiency (creatinine clearance greater than 40 mL/min) or hepatic insufficiency, the recommended dosage is 400 mg/day given in divided doses (100 mg every 6 hours). For patients with severe renal insufficiency (C cr 40 mL/min or less), the recommended dosage regimen is 100 mg at intervals shown in the table below, with or without an initial loading dose of 150 mg. DISOPYRAMIDE PHOSPHATE CAPSULES DOSAGE INTERVAL FOR PATIENTS WITH RENAL INSUFFICIENCY Creatinine clearance (mL/min) 40 to 30 30 to 15 less than 15 Approximate maintenance – dosing interval q 8 hr q 12 hr q 24 hr For patients in whom rapid control of ventricular arrhythmia is essential, an initial loading dose of 300 mg of disopyramide phosphate capsules (200 mg for patients whose body weight is less than 110 pounds) is recommended, followed by the appropriate maintenance dosage. Therapeutic effects are usually attained 30 minutes to 3 hours after administration of a 300 mg loading dose. If there is no response or evidence of toxicity within 6 hours of the loading dose, 200 mg of disopyramide phosphate capsules every 6 hours may be prescribed instead of the usual 150 mg. If there is no response to this dosage within 48 hours, either disopyramide phosphate capsules should then be discontinued or the physician should consider hospitalizing the patient for careful monitoring while subsequent disopyramide phosphate doses of 250 mg or 300 mg every 6 hours are given. A limited number of patients with severe refractory ventricular tachycardia have tolerated daily doses of disopyramide phosphate up to 1,600 mg per day (400 mg every 6 hours), resulting in disopyramide plasma levels up to 9 mcg/mL. If such treatment is warranted, it is essential that patients be hospitalized for close evaluation and continuous monitoring. Transferring to Disopyramide Phosphate The following dosage schedule based on theoretical considerations rather than experimental data is suggested for transferring patients with normal renal function from either quinidine sulfate or procainamide therapy (Type 1 antiarrhythmic agents) to disopyramide phosphate capsules therapy: Disopyramide phosphate capsules should be started using the regular maintenance schedule without a loading dose 6 to 12 hours after the last dose of quinidine sulfate or 3 to 6 hours after the last dose of procainamide. In patients in whom withdrawal of quinidine sulfate or procainamide is likely to produce life-threatening arrhythmias, the physician should consider hospitalization of the patient. Pediatric Dosage Controlled clinical studies have not been conducted in pediatric patients; however, the following suggested dosage table is based on published clinical experience. Total daily dosage should be divided and equal doses administered orally every 6 hours or at intervals according to individual patient needs. Disopyramide plasma levels and therapeutic response must be monitored closely. Patients should be hospitalized during the initial treatment period, and dose titration should start at the lower end of the ranges provided below. SUGGESTED TOTAL DAILY DOSAGE 1 Age (years) Disopyramide (mg/kg body weight/day) Under 1 10 to 30 1 to 4 10 to 20 4 to 12 10 to 15 12 to 18 6 to 15 1 Dosage is expressed in milligrams of disopyramide base. Since disopyramide phosphate 100 mg capsules contain 100 mg of disopyramide base, the pharmacist can readily prepare a 1 mg/mL to 10 mg/mL liquid suspension by adding the entire contents of disopyramide capsules to cherry syrup. (Prepare cherry syrup as follows: cherry juice, 475 mL; sucrose 800 g; alcohol 20 mL; purified water, a sufficient quantity to make 1,000 mL.) The resulting suspension, when refrigerated, is stable for one month and should be thoroughly shaken before the measurement of each dose. The suspension should be dispensed in an amber glass bottle with a child-resistant closure."],"spl_product_data_elements":["Disopyramide Phosphate Disopyramide Phosphate DISOPYRAMIDE PHOSPHATE DISOPYRAMIDE LACTOSE MONOHYDRATE MAGNESIUM STEARATE SODIUM STARCH GLYCOLATE TYPE A POTATO FERROSOFERRIC OXIDE D&C RED NO. 28 D&C RED NO. 33 D&C YELLOW NO. 10 FD&C BLUE NO. 1 GELATIN PROPYLENE GLYCOL SHELLAC SODIUM LAURYL SULFATE TITANIUM DIOXIDE light-blue scarlet 93;3127;93;3127 Disopyramide Phosphate Disopyramide Phosphate DISOPYRAMIDE PHOSPHATE DISOPYRAMIDE LACTOSE MONOHYDRATE MAGNESIUM STEARATE SODIUM STARCH GLYCOLATE TYPE A POTATO FERROSOFERRIC OXIDE D&C RED NO. 28 D&C RED NO. 33 D&C YELLOW NO. 10 FD&C BLUE NO. 1 GELATIN PROPYLENE GLYCOL SHELLAC SODIUM LAURYL SULFATE TITANIUM DIOXIDE buff scarlet 93;3129;93;3129"],"dosage_and_administration_table":["
DISOPYRAMIDE PHOSPHATE CAPSULES DOSAGE INTERVAL FOR PATIENTS WITH RENAL INSUFFICIENCY
Creatinine clearance (mL/min)40 to 3030 to 15less than 15
Approximate maintenance – dosing intervalq 8 hrq 12 hrq 24 hr
","
SUGGESTED TOTAL DAILY DOSAGE1
Age (years)Disopyramide (mg/kg body weight/day)
Under 110 to 30
1 to 410 to 20
4 to 1210 to 15
12 to 186 to 15
1 Dosage is expressed in milligrams of disopyramide base. Since disopyramide phosphate 100 mg capsules contain 100 mg of disopyramide base, the pharmacist can readily prepare a 1 mg/mL to 10 mg/mL liquid suspension by adding the entire contents of disopyramide capsules to cherry syrup. (Prepare cherry syrup as follows: cherry juice, 475 mL; sucrose 800 g; alcohol 20 mL; purified water, a sufficient quantity to make 1,000 mL.) The resulting suspension, when refrigerated, is stable for one month and should be thoroughly shaken before the measurement of each dose. The suspension should be dispensed in an amber glass bottle with a child-resistant closure.
"],"package_label_principal_display_panel":["Package/Label Display Panel NDC 0093-3127-01 Disopyramide Phosphate Capsules, USP 100 mg* Rx only 100 Capsules 1","Package/Label Display Panel NDC 0093-3129-01 Disopyramide Phosphate Capsules, USP 150 mg* Rx only 100 Capsules 1"],"carcinogenesis_and_mutagenesis_and_impairment_of_fertility":["Carcinogenesis, Mutagenesis, Impairment of Fertility Eighteen months of disopyramide phosphate administration to rats, at oral doses up to 400 mg/kg/day (about 30 times the usual daily human dose of 600 mg/day, assuming a patient weight of at least 50 kg), revealed no evidence of carcinogenic potential. An evaluation of mutagenic potential by Ames test was negative. disopyramide phosphate, at doses up to 250 mg/kg/day, did not adversely affect fertility of rats."]},"tags":[],"fdaNDC":[{"route":["ORAL"],"labeler":"Pfizer Laboratories Div Pfizer Inc","brandName":"Norpace CR","packaging":[{"ndc":"0025-2732-31","description":"100 CAPSULE, EXTENDED RELEASE in 1 BOTTLE (0025-2732-31)","marketingStartDate":"19820720"}],"dosageForm":"CAPSULE, EXTENDED RELEASE","genericName":"disopyramide phosphate","productType":"HUMAN PRESCRIPTION DRUG","activeIngredients":[{"name":"DISOPYRAMIDE PHOSPHATE","strength":"100 mg/1"}],"marketingCategory":"NDA"},{"route":[],"labeler":"Archimica S.p.A.","brandName":"","packaging":[{"ndc":"55512-0004-0","description":"50 kg in 1 DRUM (55512-0004-0)","marketingStartDate":"09-SEP-09"}],"dosageForm":"POWDER","genericName":"Disopyramide Phosphate","productType":"BULK INGREDIENT","activeIngredients":[{"name":"DISOPYRAMIDE PHOSPHATE","strength":"50 kg/50kg"}],"marketingCategory":"BULK INGREDIENT"},{"route":[],"labeler":"PCAS FINLAND","brandName":"","packaging":[{"ndc":"51014-7863-0","description":"45 kg in 1 DRUM (51014-7863-0)","marketingStartDate":"26-APR-10"}],"dosageForm":"POWDER","genericName":"DISOPYRAMIDE PHOSPHATE","productType":"BULK INGREDIENT","activeIngredients":[{"name":"DISOPYRAMIDE PHOSPHATE","strength":"1 kg/kg"}],"marketingCategory":"BULK INGREDIENT"},{"route":["ORAL"],"labeler":"Pfizer Laboratories Div Pfizer Inc","brandName":"Norpace","packaging":[{"ndc":"0025-2762-31","description":"100 CAPSULE, GELATIN COATED in 1 BOTTLE (0025-2762-31)","marketingStartDate":"19770901"}],"dosageForm":"CAPSULE, GELATIN COATED","genericName":"disopyramide phosphate","productType":"HUMAN PRESCRIPTION DRUG","activeIngredients":[{"name":"DISOPYRAMIDE PHOSPHATE","strength":"150 mg/1"}],"marketingCategory":"NDA"},{"route":["ORAL"],"labeler":"Dr. Reddy's Labratories Inc.","brandName":"DISOPYRAMIDE PHOSPHATE","packaging":[{"ndc":"75907-026-01","description":"100 CAPSULE in 1 BOTTLE (75907-026-01)","marketingStartDate":"20240315"}],"dosageForm":"CAPSULE","genericName":"DISOPYRAMIDE PHOSPHATE","productType":"HUMAN PRESCRIPTION DRUG","activeIngredients":[{"name":"DISOPYRAMIDE PHOSPHATE","strength":"150 mg/1"}],"marketingCategory":"ANDA"},{"route":["ORAL"],"labeler":"Dr. Reddy's Labratories Inc.","brandName":"DISOPYRAMIDE PHOSPHATE","packaging":[{"ndc":"75907-027-01","description":"100 CAPSULE in 1 BOTTLE (75907-027-01)","marketingStartDate":"20240315"}],"dosageForm":"CAPSULE","genericName":"DISOPYRAMIDE PHOSPHATE","productType":"HUMAN PRESCRIPTION DRUG","activeIngredients":[{"name":"DISOPYRAMIDE PHOSPHATE","strength":"100 mg/1"}],"marketingCategory":"ANDA"},{"route":["ORAL"],"labeler":"Mayne Pharma Commercial LLC","brandName":"DISOPYRAMIDE PHOSPHATE","packaging":[{"ndc":"51862-095-01","description":"100 CAPSULE in 1 BOTTLE (51862-095-01)","marketingStartDate":"20220401"}],"dosageForm":"CAPSULE","genericName":"DISOPYRAMIDE PHOSPHATE","productType":"HUMAN PRESCRIPTION DRUG","activeIngredients":[{"name":"DISOPYRAMIDE PHOSPHATE","strength":"100 mg/1"}],"marketingCategory":"ANDA"},{"route":["ORAL"],"labeler":"Pfizer Laboratories Div Pfizer Inc","brandName":"Norpace CR","packaging":[{"ndc":"0025-2742-31","description":"100 CAPSULE, EXTENDED RELEASE in 1 BOTTLE (0025-2742-31)","marketingStartDate":"19820720"}],"dosageForm":"CAPSULE, EXTENDED RELEASE","genericName":"disopyramide phosphate","productType":"HUMAN PRESCRIPTION DRUG","activeIngredients":[{"name":"DISOPYRAMIDE PHOSPHATE","strength":"150 mg/1"}],"marketingCategory":"NDA"},{"route":[],"labeler":"Sumitomo Chemical Company, Limited","brandName":"","packaging":[{"ndc":"68259-1304-1","description":"50 kg in 1 CONTAINER (68259-1304-1)","marketingStartDate":"18-JUN-09"}],"dosageForm":"POWDER","genericName":"Disopyramide Phosphate","productType":"BULK INGREDIENT","activeIngredients":[{"name":"DISOPYRAMIDE PHOSPHATE","strength":"1 kg/kg"}],"marketingCategory":"BULK INGREDIENT"},{"route":["ORAL"],"labeler":"Mylan Pharmaceuticals Inc.","brandName":"Disopyramide Phosphate","packaging":[{"ndc":"59762-0386-1","description":"100 CAPSULE, GELATIN COATED in 1 BOTTLE (59762-0386-1)","marketingStartDate":"20190423"}],"dosageForm":"CAPSULE, GELATIN COATED","genericName":"disopyramide phosphate","productType":"HUMAN PRESCRIPTION DRUG","activeIngredients":[{"name":"DISOPYRAMIDE PHOSPHATE","strength":"100 mg/1"}],"marketingCategory":"NDA AUTHORIZED GENERIC"},{"route":["ORAL"],"labeler":"Mylan Pharmaceuticals Inc.","brandName":"Disopyramide Phosphate","packaging":[{"ndc":"59762-0400-1","description":"100 CAPSULE, GELATIN COATED in 1 BOTTLE (59762-0400-1)","marketingStartDate":"20190423"}],"dosageForm":"CAPSULE, GELATIN COATED","genericName":"disopyramide phosphate","productType":"HUMAN PRESCRIPTION DRUG","activeIngredients":[{"name":"DISOPYRAMIDE PHOSPHATE","strength":"150 mg/1"}],"marketingCategory":"NDA AUTHORIZED GENERIC"},{"route":["ORAL"],"labeler":"Teva Pharmaceuticals USA, Inc.","brandName":"Disopyramide Phosphate","packaging":[{"ndc":"0093-3127-01","description":"100 CAPSULE in 1 BOTTLE (0093-3127-01)","marketingStartDate":"19900930"}],"dosageForm":"CAPSULE","genericName":"Disopyramide Phosphate","productType":"HUMAN PRESCRIPTION DRUG","activeIngredients":[{"name":"DISOPYRAMIDE PHOSPHATE","strength":"100 mg/1"}],"marketingCategory":"ANDA"},{"route":["ORAL"],"labeler":"Teva Pharmaceuticals USA, Inc.","brandName":"Disopyramide Phosphate","packaging":[{"ndc":"0093-3129-01","description":"100 CAPSULE in 1 BOTTLE (0093-3129-01)","marketingStartDate":"19900930"}],"dosageForm":"CAPSULE","genericName":"Disopyramide Phosphate","productType":"HUMAN PRESCRIPTION DRUG","activeIngredients":[{"name":"DISOPYRAMIDE PHOSPHATE","strength":"150 mg/1"}],"marketingCategory":"ANDA"},{"route":["ORAL"],"labeler":"Pfizer Laboratories Div Pfizer Inc","brandName":"Norpace","packaging":[{"ndc":"0025-2752-31","description":"100 CAPSULE, GELATIN COATED in 1 BOTTLE (0025-2752-31)","marketingStartDate":"19770901"}],"dosageForm":"CAPSULE, GELATIN COATED","genericName":"disopyramide phosphate","productType":"HUMAN PRESCRIPTION DRUG","activeIngredients":[{"name":"DISOPYRAMIDE PHOSPHATE","strength":"100 mg/1"}],"marketingCategory":"NDA"}],"safety":{"boxedWarnings":["Mortality In the National Heart, Lung and Blood Institute's Cardiac Arrhythmia Suppression Trial (CAST), a long-term, multi-center, randomized, double-blind study in patients with asymptomatic non-life-threatening ventricular arrhythmias who had had a myocardial infarction more than 6 days but less than 2 years previously, an excessive mortality or non-fatal cardiac arrest rate (7.7%) was seen in patients treated with encainide or flecainide compared with that seen in patients assigned to carefu"],"safetySignals":[{"date":"","signal":"DRUG INEFFECTIVE","source":"FDA FAERS","actionTaken":"148 reports"},{"date":"","signal":"OFF LABEL USE","source":"FDA FAERS","actionTaken":"75 reports"},{"date":"","signal":"ATRIAL FIBRILLATION","source":"FDA FAERS","actionTaken":"59 reports"},{"date":"","signal":"DYSPNOEA","source":"FDA FAERS","actionTaken":"53 reports"},{"date":"","signal":"FATIGUE","source":"FDA FAERS","actionTaken":"46 reports"},{"date":"","signal":"MALAISE","source":"FDA FAERS","actionTaken":"45 reports"},{"date":"","signal":"DIZZINESS","source":"FDA FAERS","actionTaken":"37 reports"},{"date":"","signal":"PALPITATIONS","source":"FDA FAERS","actionTaken":"34 reports"},{"date":"","signal":"ASTHENIA","source":"FDA FAERS","actionTaken":"33 reports"},{"date":"","signal":"FEELING ABNORMAL","source":"FDA FAERS","actionTaken":"29 reports"},{"date":"","signal":"HEADACHE","source":"FDA FAERS","actionTaken":"25 reports"},{"date":"","signal":"CONSTIPATION","source":"FDA FAERS","actionTaken":"24 reports"},{"date":"","signal":"DRY MOUTH","source":"FDA FAERS","actionTaken":"24 reports"},{"date":"","signal":"DRUG INTERACTION","source":"FDA FAERS","actionTaken":"23 reports"},{"date":"","signal":"PRODUCT USE ISSUE","source":"FDA FAERS","actionTaken":"23 reports"},{"date":"","signal":"DRUG INEFFECTIVE FOR UNAPPROVED INDICATION","source":"FDA FAERS","actionTaken":"22 reports"},{"date":"","signal":"LOSS OF CONSCIOUSNESS","source":"FDA FAERS","actionTaken":"22 reports"},{"date":"","signal":"PRODUCT USE IN UNAPPROVED INDICATION","source":"FDA FAERS","actionTaken":"22 reports"},{"date":"","signal":"CHEST PAIN","source":"FDA FAERS","actionTaken":"21 reports"},{"date":"","signal":"CONDITION AGGRAVATED","source":"FDA FAERS","actionTaken":"21 reports"},{"date":"","signal":"NAUSEA","source":"FDA FAERS","actionTaken":"21 reports"},{"date":"","signal":"DIARRHOEA","source":"FDA FAERS","actionTaken":"20 reports"},{"date":"","signal":"WEIGHT DECREASED","source":"FDA FAERS","actionTaken":"20 reports"},{"date":"","signal":"ARRHYTHMIA","source":"FDA FAERS","actionTaken":"18 reports"},{"date":"","signal":"HEART RATE IRREGULAR","source":"FDA FAERS","actionTaken":"18 reports"},{"date":"","signal":"INTENTIONAL PRODUCT MISUSE","source":"FDA FAERS","actionTaken":"18 reports"},{"date":"","signal":"PAIN IN EXTREMITY","source":"FDA FAERS","actionTaken":"18 reports"},{"date":"","signal":"PNEUMONIA","source":"FDA FAERS","actionTaken":"18 reports"},{"date":"","signal":"ANXIETY","source":"FDA FAERS","actionTaken":"17 reports"},{"date":"","signal":"BLOOD PRESSURE INCREASED","source":"FDA FAERS","actionTaken":"17 reports"},{"date":"","signal":"CEREBROVASCULAR ACCIDENT","source":"FDA FAERS","actionTaken":"17 reports"},{"date":"","signal":"FALL","source":"FDA FAERS","actionTaken":"17 reports"},{"date":"","signal":"HEART RATE INCREASED","source":"FDA FAERS","actionTaken":"17 reports"},{"date":"","signal":"PAIN","source":"FDA FAERS","actionTaken":"17 reports"},{"date":"","signal":"SYNCOPE","source":"FDA FAERS","actionTaken":"17 reports"},{"date":"","signal":"PRODUCT DOSE OMISSION ISSUE","source":"FDA FAERS","actionTaken":"16 reports"},{"date":"","signal":"DEATH","source":"FDA FAERS","actionTaken":"15 reports"},{"date":"","signal":"DRUG HYPERSENSITIVITY","source":"FDA FAERS","actionTaken":"15 reports"},{"date":"","signal":"ELECTROCARDIOGRAM QT PROLONGED","source":"FDA FAERS","actionTaken":"15 reports"},{"date":"","signal":"VISION BLURRED","source":"FDA FAERS","actionTaken":"15 reports"},{"date":"","signal":"WEIGHT INCREASED","source":"FDA FAERS","actionTaken":"15 reports"},{"date":"","signal":"CARDIAC DISORDER","source":"FDA FAERS","actionTaken":"14 reports"},{"date":"","signal":"BRADYCARDIA","source":"FDA FAERS","actionTaken":"13 reports"},{"date":"","signal":"DRUG INTOLERANCE","source":"FDA FAERS","actionTaken":"13 reports"},{"date":"","signal":"GAIT DISTURBANCE","source":"FDA FAERS","actionTaken":"13 reports"},{"date":"","signal":"HYPOGLYCAEMIA","source":"FDA FAERS","actionTaken":"13 reports"},{"date":"","signal":"INSOMNIA","source":"FDA FAERS","actionTaken":"13 reports"},{"date":"","signal":"PRODUCT DISPENSING ERROR","source":"FDA FAERS","actionTaken":"13 reports"},{"date":"","signal":"RASH","source":"FDA FAERS","actionTaken":"13 reports"},{"date":"","signal":"CHEST DISCOMFORT","source":"FDA FAERS","actionTaken":"12 reports"}],"drugInteractions":[{"drug":"Phenytoin and other hepatic enzyme inducers","severity":"moderate","mechanism":"Hepatic enzyme induction","management":"Monitor disopyramide plasma levels during concurrent use","clinicalEffect":"Lower plasma levels of disopyramide may occur, potentially leading to ineffective therapy"},{"drug":"Other antiarrhythmic drugs (quinidine, procainamide, lidocaine, propranolol)","severity":"major","mechanism":"Additive cardiac effects","management":"Use with caution; monitor cardiac parameters","clinicalEffect":"Excessive widening of QRS complex and/or prolongation of Q-T interval may occur"},{"drug":"Verapamil","severity":"major","mechanism":"Unknown potential interaction","management":"Do not administer disopyramide within 48 hours before or 24 hours after verapamil administration","clinicalEffect":"Possible serious interaction"},{"drug":"Clarithromycin and erythromycin","severity":"major","mechanism":"Inhibition of cytochrome P450 3A4 metabolism","management":"Avoid coadministration; do not use together","clinicalEffect":"Life-threatening interactions reported; increased disopyramide levels"},{"drug":"Ketoconazole and other potent CYP3A4 inhibitors","severity":"major","mechanism":"Inhibition of cytochrome P450 3A4 metabolism","management":"Avoid coadministration","clinicalEffect":"Potentially fatal interaction possible based on in vitro studies"}],"commonSideEffects":[{"effect":"Headache","drugRate":"21.4%","severity":"common","organSystem":""},{"effect":"Dizziness","drugRate":"21.4%","severity":"common","organSystem":""},{"effect":"Bursitis","drugRate":"16.7%","severity":"common","organSystem":""},{"effect":"Arthralgia","drugRate":"15.4%","severity":"common","organSystem":""},{"effect":"Diarrhoea","drugRate":"14.3%","severity":"common","organSystem":""},{"effect":"Bowel movement irregularity","drugRate":"14.3%","severity":"common","organSystem":""},{"effect":"Nausea","drugRate":"14.3%","severity":"common","organSystem":""},{"effect":"Anxiety","drugRate":"14.3%","severity":"common","organSystem":""},{"effect":"Insomnia","drugRate":"14.3%","severity":"common","organSystem":""},{"effect":"Atrial fibrillation","drugRate":"14.3%","severity":"common","organSystem":""},{"effect":"Palpitations","drugRate":"14.3%","severity":"common","organSystem":""},{"effect":"Pain in extremity","drugRate":"14.3%","severity":"common","organSystem":""},{"effect":"Viral upper respiratory tract infection","drugRate":"14.3%","severity":"common","organSystem":""},{"effect":"Constipation","drugRate":"7.7%","severity":"common","organSystem":""},{"effect":"Defaecation urgency","drugRate":"7.7%","severity":"common","organSystem":""}],"contraindications":["Cardiogenic shock","Preexisting second- or third-degree AV block (if no pacemaker is present)","Congenital Q-T prolongation","Known hypersensitivity to the drug"],"specialPopulations":{"Nursing":"Nursing Mothers Studies in rats have shown that the concentration of disopyramide and its metabolites is between one and three times greater in milk than it is in plasma. Following oral administration, disopyramide has been detected in human milk at a concentration not exceeding that in plasma. Because of the potential for serious adverse reactions in nursing infants from disopyramide phosphate, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into acco","Geriatric":"Geriatric Use Clinical studies of disopyramide phosphate did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or c","Pediatric":"Pediatric Use Safety and effectiveness in pediatric patients have not been established (see DOSAGE AND ADMINISTRATION ).","Pregnancy":"Pregnancy Teratogenic Effects Disopyramide phosphate was associated with decreased numbers of implantation sites and decreased growth and survival of pups when administered to pregnant rats at 250 mg/kg/day (20 or more times the usual daily human dose of 12 mg/kg, assuming a patient weight of at least 50 kg), a level at which weight gain and food consumption of dams were also reduced. Increased resorption rates were reported in rabbits at 60 mg/kg/day (5 or more times the usual daily human dose)"},"seriousAdverseEvents":[{"effect":"Hypotension","drugRate":"14.3%","severity":"serious"},{"effect":"Stress cardiomyopathy","drugRate":"14.3%","severity":"serious"},{"effect":"Syncope","drugRate":"14.3%","severity":"serious"},{"effect":"Acute respiratory failure","drugRate":"14.3%","severity":"serious"},{"effect":"Pulmonary oedema","drugRate":"14.3%","severity":"serious"},{"effect":"Acute coronary syndrome","drugRate":"7.1%","severity":"serious"},{"effect":"Back pain","drugRate":"7.1%","severity":"serious"},{"effect":"Atrial fibrillation","drugRate":"2.4%","severity":"serious"},{"effect":"Cardiac arrest","drugRate":"2.4%","severity":"serious"},{"effect":"Myasthenia gravis","drugRate":"2.4%","severity":"serious"}]},"trials":[],"aliases":[],"company":"Pfizer","patents":[],"pricing":[{"market":"United States","source":"CMS National Average Drug Acquisition Cost (NADAC)","asOfDate":"2024-04-17","unitCost":"$1.3307/EA","priceType":"NADAC","sourceUrl":"https://data.medicaid.gov/dataset/4j6z-xnwq","annualCost":"$486","description":"DISOPYRAMIDE 100 MG CAPSULE","retrievedDate":"2026-04-07"}],"_fixedAt":"2026-03-30T15:17:22.723566","_recalls":[{"date":"20151216","reason":"Failed Dissolution Specification","classification":"Class III"},{"date":"20130626","reason":"Failed Dissolution Specification","classification":"Class III"}],"_sources":{"fdaNDC":{"url":"","method":"api_direct","source":"FDA NDC Directory","rawText":"","confidence":1,"sourceType":"fda_ndc","retrievedAt":"2026-04-19T18:36:14.043196+00:00"},"patents":{"url":"","method":"deterministic","source":"FDA Orange Book + Purple Book","rawText":"","confidence":1,"sourceType":"fda_orange_book","retrievedAt":"2026-04-19T18:36:28.332627+00:00"},"dailyMed":{"url":"","method":"api_direct","source":"DailyMed (NIH/NLM)","rawText":"","confidence":1,"sourceType":"dailymed","retrievedAt":"2026-04-19T18:36:14.809125+00:00"},"aiSummary":{"url":"","method":"ai_extraction","source":"Haiku strategic summary","rawText":"","confidence":0.9,"sourceType":"ai_extraction","retrievedAt":"2026-04-20T07:54:19.621501+00:00"},"chemblData":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1201020/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-19T18:36:22.013604+00:00"},"fdaRecalls":{"url":"","method":"api_direct","source":"FDA Enforcement/Recalls","rawText":"","confidence":1,"sourceType":"fda_enforcement","retrievedAt":"2026-04-19T18:36:19.690467+00:00"},"overdosage":{"url":"","method":"deterministic","source":"FDA Label (overdosage)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-19T18:35:15.771653+00:00"},"howSupplied":{"url":"","method":"deterministic","source":"FDA Label (how_supplied)","rawText":"HOW SUPPLIED Disopyramide phosphate capsules, USP are supplied as: 100 mg - hard gelatin capsule with a light-blue body imprinted “93-3127” and a scarlet cap imprinted “93-3127”, containing 100 mg of disopyramide base present as the phosphate, in bottles of 100 (NDC 0093-3127-01). 150 mg - hard gelatin capsule with a scarlet body imprinted “93-3129” and a buff cap imprinted “93-3129”, containing 150 mg of disopyramide base present as the phosphate, in bottles of 100 (NDC 0093-3129-01). Storage S","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-19T18:35:04.312287+00:00"},"trialDetails":{"url":"","method":"deterministic","source":"ClinicalTrials.gov (0 trials with endpoints)","rawText":"","confidence":1,"sourceType":"ctgov_results","retrievedAt":"2026-04-19T18:36:41.176092+00:00"},"drugDescription":{"url":"","method":"ai_extraction","source":"FDA Label (description)","aiModel":"featherless","rawText":"DESCRIPTION Disopyramide phosphate, USP is an antiarrhythmic drug available for oral administration in capsules containing 100 mg or 150 mg of disopyramide base, present as the phosphate. The base content of the phosphate salt is 77.6%. The structural formula of disopyramide phosphate, USP is: C 21 H 29 N 3 O•H 3 PO 4 M.W. 437.47 α-[2-(diisopropylamino) ethyl]-α-phenyl-2-pyridineacetamide phosphate Disopyramide phosphate, USP is freely soluble in water, and the free base (pKa 10.4) has an aqueou","confidence":0.95,"sourceType":"fda_label","retrievedAt":"2026-04-19T18:35:15.771563+00:00"},"pharmacokinetics":{"url":"","method":"ai_extraction","source":"FDA Label (pharmacokinetics)","aiModel":"featherless","rawText":"CLINICAL PHARMACOLOGY Mechanisms of Action Disopyramide phosphate is a Type 1 antiarrhythmic drug (i.e., similar to procainamide and quinidine). In animal studies, disopyramide phosphate decreases the rate of diastolic depolarization (phase 4) in cells with augmented automaticity, decreases the upstroke velocity (phase 0) and increases the action potential duration of normal cardiac cells, decreases the disparity in refractoriness between infarcted and adjacent normally perfused myocardium, and ","confidence":0.95,"sourceType":"fda_label","retrievedAt":"2026-04-19T18:35:04.312195+00:00"},"publicationCount":{"url":"","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-19T18:36:19.808197+00:00"},"faersTotalReports":{"url":"","method":"api_direct","source":"FDA FAERS","rawText":"","confidence":1,"sourceType":"fda_faers","retrievedAt":"2026-04-19T18:36:19.320009+00:00"},"recentPublications":{"url":"","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-19T18:36:20.769489+00:00"},"participantFlowData":{"url":"","method":"deterministic","source":"ClinicalTrials.gov participantFlowModule","rawText":"","confidence":1,"sourceType":"ctgov_results","retrievedAt":"2026-04-19T18:36:41.176081+00:00"},"safety.safetySignals":{"url":"","method":"api_direct","source":"FDA FAERS","rawText":"","confidence":1,"sourceType":"fda_faers","retrievedAt":"2026-04-19T18:36:15.699033+00:00"},"nonclinicalToxicology":{"url":"","method":"deterministic","source":"FDA Label (nonclinical_toxicology)","rawText":"Carcinogenesis, Mutagenesis, Impairment of Fertility Eighteen months of disopyramide phosphate administration to rats, at oral doses up to 400 mg/kg/day (about 30 times the usual daily human dose of 600 mg/day, assuming a patient weight of at least 50 kg), revealed no evidence of carcinogenic potential. An evaluation of mutagenic potential by Ames test was negative. disopyramide phosphate, at doses up to 250 mg/kg/day, did not adversely affect fertility of rats.","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-19T18:35:15.771648+00:00"},"structuredTrialResults":{"url":"","method":"deterministic","source":"ClinicalTrials.gov resultsSection (0 trials)","rawText":"","confidence":1,"sourceType":"ctgov_results","retrievedAt":"2026-04-19T18:36:41.176079+00:00"},"safety.drugInteractions":{"url":"","method":"ai_extraction","source":"FDA Label + Haiku","rawText":"","confidence":0.95,"sourceType":"fda_label","retrievedAt":"2026-04-20T07:54:19.621497+00:00"},"safety.commonSideEffects":{"url":"","method":"deterministic","source":"ClinicalTrials.gov (0 trials with results)","rawText":"","confidence":1,"sourceType":"ctgov_results","retrievedAt":"2026-04-19T18:36:41.176034+00:00"},"safety.contraindications":{"url":"","method":"ai_extraction","source":"FDA Label + Haiku","rawText":"","confidence":0.95,"sourceType":"fda_label","retrievedAt":"2026-04-20T07:54:19.621475+00:00"},"safety.specialPopulations":{"url":"","method":"deterministic","source":"FDA Label (special populations)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-19T18:36:07.630240+00:00"},"safety.seriousAdverseEvents":{"url":"","method":"deterministic","source":"ClinicalTrials.gov (0 trials)","rawText":"","confidence":1,"sourceType":"ctgov_results","retrievedAt":"2026-04-19T18:36:41.176057+00:00"}},"allNames":"norpace cr","dailyMed":[{"url":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=31e79459-107f-4d69-a163-90014f1c4772","setid":"31e79459-107f-4d69-a163-90014f1c4772","title":"DISOPYRAMIDE PHOSPHATE CAPSULE, GELATIN COATED [MYLAN PHARMACEUTICALS INC.]"},{"url":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e2aa1642-d262-4520-bc6a-9fd3ad795677","setid":"e2aa1642-d262-4520-bc6a-9fd3ad795677","title":"NORPACE (DISOPYRAMIDE PHOSPHATE) CAPSULE, GELATIN COATED NORPACE CR (DISOPYRAMIDE PHOSPHATE) CAPSULE, EXTENDED RELEASE [PFIZER LABORATORIES DIV PFIZER INC]"},{"url":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7d550b12-065a-416c-93fa-b61368eeb36f","setid":"7d550b12-065a-416c-93fa-b61368eeb36f","title":"DISOPYRAMIDE PHOSPHATE CAPSULE [MAYNE PHARMA COMMERCIAL LLC]"},{"url":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=11a68e26-d2e4-48f6-ba0f-9bdd5778f25a","setid":"11a68e26-d2e4-48f6-ba0f-9bdd5778f25a","title":"DISOPYRAMIDE PHOSPHATE CAPSULE [TEVA PHARMACEUTICALS USA, INC.]"},{"url":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3acbcef2-04ec-1ab1-b855-d1244b0e8006","setid":"3acbcef2-04ec-1ab1-b855-d1244b0e8006","title":"DISOPYRAMIDE PHOSPHATE CAPSULE [DR. REDDY'S LABRATORIES INC.]"}],"offLabel":[],"synonyms":["disopyramide","dicorantil","disopyramide phosphate","disopyramide tartrate","disopyramide monohydrochloride","disopyramide hydrochloride"],"timeline":[{"date":"1972-01-01","type":"neutral","_source":"Wikipedia","milestone":"Disopyramide approved","regulator":"none"},{"date":"1977-09-01","type":"positive","_source":"FDA NDA017447","milestone":"FDA ORIG — PFIZER","regulator":"FDA","description":""},{"date":"1978-03-02","type":"positive","_source":"FDA NDA017447","milestone":"FDA SUPPL — PFIZER","regulator":"FDA","description":""},{"date":"1979-04-26","type":"positive","_source":"FDA NDA017447","milestone":"FDA SUPPL — PFIZER","regulator":"FDA","description":""},{"date":"1980-01-30","type":"positive","_source":"FDA NDA017447","milestone":"FDA SUPPL — PFIZER","regulator":"FDA","description":""},{"date":"1981-01-30","type":"positive","_source":"FDA NDA017447","milestone":"FDA SUPPL — PFIZER","regulator":"FDA","description":""},{"date":"1982-06-17","type":"positive","_source":"FDA NDA017447","milestone":"FDA SUPPL — PFIZER","regulator":"FDA","description":""},{"date":"1982-07-20","type":"positive","_source":"FDA NDA018655","milestone":"FDA ORIG — PFIZER","regulator":"FDA","description":""},{"date":"1983-03-10","type":"positive","_source":"FDA NDA018655","milestone":"FDA SUPPL — PFIZER","regulator":"FDA","description":""},{"date":"1984-02-29","type":"positive","_source":"FDA NDA018655","milestone":"FDA SUPPL — PFIZER","regulator":"FDA","description":""},{"date":"1985-01-25","type":"positive","_source":"FDA NDA018655","milestone":"FDA SUPPL — PFIZER","regulator":"FDA","description":""},{"date":"1985-02-22","type":"positive","_source":"FDA ANDA070101","milestone":"FDA ORIG — TEVA","regulator":"FDA","description":""},{"date":"1985-05-20","type":"positive","_source":"FDA ANDA070101","milestone":"FDA SUPPL — TEVA","regulator":"FDA","description":""},{"date":"1985-05-31","type":"positive","_source":"FDA ANDA070173","milestone":"FDA ORIG — DR REDDYS LABS SA","regulator":"FDA","description":""},{"date":"1985-07-24","type":"positive","_source":"FDA ANDA070173","milestone":"FDA SUPPL — DR REDDYS LABS SA","regulator":"FDA","description":""},{"date":"1986-04-14","type":"positive","_source":"FDA ANDA070101","milestone":"FDA SUPPL — TEVA","regulator":"FDA","description":""},{"date":"1986-04-16","type":"positive","_source":"FDA ANDA070173","milestone":"FDA SUPPL — DR REDDYS LABS SA","regulator":"FDA","description":""},{"date":"1986-05-06","type":"positive","_source":"FDA NDA018655","milestone":"FDA SUPPL — PFIZER","regulator":"FDA","description":""},{"date":"1987-02-12","type":"positive","_source":"FDA NDA018655","milestone":"FDA SUPPL — PFIZER","regulator":"FDA","description":""},{"date":"1987-10-30","type":"positive","_source":"FDA ANDA070101","milestone":"FDA SUPPL — TEVA","regulator":"FDA","description":""},{"date":"1988-02-04","type":"positive","_source":"FDA NDA018655","milestone":"FDA SUPPL — PFIZER","regulator":"FDA","description":""},{"date":"1988-07-06","type":"positive","_source":"FDA ANDA070101","milestone":"FDA SUPPL — TEVA","regulator":"FDA","description":""},{"date":"1988-07-12","type":"positive","_source":"FDA ANDA070173","milestone":"FDA SUPPL — DR REDDYS LABS SA","regulator":"FDA","description":""},{"date":"1989-10-20","type":"positive","_source":"FDA NDA018655","milestone":"FDA SUPPL — PFIZER","regulator":"FDA","description":""},{"date":"1990-06-29","type":"positive","_source":"FDA ANDA070173","milestone":"FDA SUPPL — DR REDDYS LABS SA","regulator":"FDA","description":""},{"date":"1990-10-03","type":"positive","_source":"FDA ANDA070101","milestone":"FDA SUPPL — TEVA","regulator":"FDA","description":""},{"date":"1991-01-28","type":"positive","_source":"FDA ANDA070173","milestone":"FDA SUPPL — DR REDDYS LABS SA","regulator":"FDA","description":""},{"date":"1991-05-30","type":"positive","_source":"FDA ANDA070101","milestone":"FDA SUPPL — TEVA","regulator":"FDA","description":""},{"date":"1991-07-03","type":"positive","_source":"FDA NDA018655","milestone":"FDA SUPPL — PFIZER","regulator":"FDA","description":""},{"date":"1992-01-16","type":"positive","_source":"FDA NDA018655","milestone":"FDA SUPPL — PFIZER","regulator":"FDA","description":""},{"date":"1992-06-11","type":"positive","_source":"FDA ANDA070101","milestone":"FDA SUPPL — TEVA","regulator":"FDA","description":""},{"date":"1992-11-24","type":"positive","_source":"FDA ANDA070173","milestone":"FDA SUPPL — DR REDDYS LABS SA","regulator":"FDA","description":""},{"date":"1993-12-21","type":"positive","_source":"FDA NDA018655","milestone":"FDA SUPPL — PFIZER","regulator":"FDA","description":""},{"date":"1995-01-23","type":"positive","_source":"FDA ANDA070101","milestone":"FDA SUPPL — TEVA","regulator":"FDA","description":""},{"date":"1996-02-09","type":"positive","_source":"FDA NDA017447","milestone":"FDA SUPPL — PFIZER","regulator":"FDA","description":""},{"date":"1996-07-12","type":"positive","_source":"FDA ANDA070101","milestone":"FDA SUPPL — TEVA","regulator":"FDA","description":""},{"date":"1996-10-23","type":"positive","_source":"FDA ANDA070173","milestone":"FDA SUPPL — DR REDDYS LABS SA","regulator":"FDA","description":""},{"date":"1997-01-13","type":"positive","_source":"FDA NDA018655","milestone":"FDA SUPPL — PFIZER","regulator":"FDA","description":""},{"date":"1997-04-07","type":"positive","_source":"FDA ANDA070101","milestone":"FDA SUPPL — TEVA","regulator":"FDA","description":""},{"date":"1997-11-14","type":"positive","_source":"FDA ANDA070173","milestone":"FDA SUPPL — DR REDDYS LABS SA","regulator":"FDA","description":""},{"date":"1998-02-03","type":"positive","_source":"FDA NDA018655","milestone":"FDA SUPPL — PFIZER","regulator":"FDA","description":""},{"date":"1998-02-17","type":"positive","_source":"FDA ANDA070173","milestone":"FDA SUPPL — DR REDDYS LABS SA","regulator":"FDA","description":""},{"date":"1999-03-03","type":"positive","_source":"FDA ANDA070173","milestone":"FDA SUPPL — DR REDDYS LABS SA","regulator":"FDA","description":""},{"date":"1999-04-30","type":"positive","_source":"FDA ANDA070101","milestone":"FDA SUPPL — TEVA","regulator":"FDA","description":""},{"date":"2000-05-16","type":"positive","_source":"FDA ANDA070101","milestone":"FDA SUPPL — TEVA","regulator":"FDA","description":""},{"date":"2000-05-17","type":"positive","_source":"FDA NDA018655","milestone":"FDA SUPPL — PFIZER","regulator":"FDA","description":""},{"date":"2000-09-12","type":"positive","_source":"FDA ANDA070173","milestone":"FDA SUPPL — DR REDDYS LABS SA","regulator":"FDA","description":""},{"date":"2001-01-11","type":"positive","_source":"FDA ANDA070173","milestone":"FDA SUPPL — DR REDDYS LABS SA","regulator":"FDA","description":""},{"date":"2001-02-08","type":"positive","_source":"FDA ANDA070101","milestone":"FDA SUPPL — TEVA","regulator":"FDA","description":""},{"date":"2007-02-08","type":"positive","_source":"FDA ANDA070102","milestone":"FDA SUPPL — TEVA","regulator":"FDA","description":""},{"date":"2015-04-29","type":"positive","_source":"FDA ANDA070101","milestone":"FDA SUPPL — TEVA","regulator":"FDA","description":""}],"variants":[{"slug":"norpace-cr","route":"Oral","brandName":"Norpace Cr","description":"Norpace Cr","formulation":"Capsule"}],"_dailymed":{"setId":"31e79459-107f-4d69-a163-90014f1c4772","title":"DISOPYRAMIDE PHOSPHATE CAPSULE, GELATIN COATED [MYLAN PHARMACEUTICALS INC.]","labeler":""},"aiSummary":"Disopyramide phosphate is indicated for treatment of documented life-threatening ventricular arrhythmias such as sustained ventricular tachycardia. The drug carries significant risks including hypotension, congestive heart failure, and anticholinergic effects, with urinary retention being the most serious anticholinergic adverse effect. Major drug interactions exist with CYP3A4 inhibitors (clarithromycin, erythromycin, ketoconazole) that can result in life-threatening complications, and verapamil must be avoided within specific timeframes. Hospital initiation is required due to proarrhythmic potential and serious adverse reaction profile.","brandName":"Norpace Cr","ecosystem":[],"isGeneric":true,"mechanism":{"target":"G protein-activated inward rectifier potassium channel 4","novelty":"Best-in-class","targets":[{"gene":"KCNJ5","source":"DrugCentral","target":"G protein-activated inward rectifier potassium channel 4","protein":"G protein-activated inward rectifier potassium channel 4","activityType":"IC50"},{"gene":"HRH1","source":"DrugCentral","target":"Histamine H1 receptor","protein":"Histamine H1 receptor","activityType":"Ki"},{"gene":"CHRM1","source":"DrugCentral","target":"Muscarinic acetylcholine receptor M1","protein":"Muscarinic acetylcholine receptor M1","activityType":""},{"gene":"CHRM2","source":"DrugCentral","target":"Muscarinic acetylcholine receptor M2","protein":"Muscarinic acetylcholine receptor M2","activityType":""},{"gene":"CHRM3","source":"DrugCentral","target":"Muscarinic acetylcholine receptor M3","protein":"Muscarinic acetylcholine receptor M3","activityType":""},{"gene":"KCNH2","source":"DrugCentral","target":"Potassium voltage-gated channel subfamily H member 2","protein":"Potassium voltage-gated channel subfamily H member 2","activityType":"IC50"},{"gene":"HCN4","source":"DrugCentral","target":"Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4","protein":"Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4","activityType":"IC50"},{"gene":"SCN5A","source":"DrugCentral","target":"Sodium channel protein type 5 subunit alpha","protein":"Sodium channel protein type 5 subunit alpha","activityType":""},{"gene":"SLC22A1","source":"DrugCentral","target":"Solute carrier family 22 member 1","protein":"Solute carrier family 22 member 1","activityType":"IC50"}],"modality":"Small molecule","drugClass":"High Risk QT Prolonging Agents","explanation":"Norpace works by blocking sodium channels in the heart, which helps to regulate the heart's rhythm. This is achieved through its mechanism of action as a Class 1a anti-arrhythmic agent. By blocking sodium channels, Norpace decreases the rate of diastolic depolarization and upstroke velocity, and increases the action potential duration of normal cardiac cells.","oneSentence":"Norpace is a sodium channel blocker and a Class 1a anti-arrhythmic agent.","technicalDetail":"Norpace exerts its effects by binding to sodium channels in the heart, specifically the Nav1.5 subunit. This binding blocks the flow of sodium ions into the cell, which helps to regulate the heart's rhythm. As a result, Norpace decreases the rate of diastolic depolarization and upstroke velocity, and increases the action potential duration of normal cardiac cells."},"_companyIR":{"url":"https://www.pfizer.com/investors","revenueRefs":[],"pipelineRefs":[]},"_wikipedia":{"title":"Disopyramide","extract":"Disopyramide is an antiarrhythmic medication used in the treatment of ventricular tachycardia. It is a sodium channel blocker and is classified as a Class 1a anti-arrhythmic agent. Disopyramide has a negative inotropic effect on the ventricular myocardium, significantly decreasing the contractility. Disopyramide also has general anticholinergic effects which contribute to unwanted adverse effects. Disopyramide is available in both oral and intravenous forms. In 1972, when it was one of the few alternatives to quinidine, it was praised for being more potent and somewhat less toxic. However, a 2012 review of antiarrhythmic drugs noted that disopyramide is among the most toxic agents, with a high burden of side effects and increased mortality when used to treat atrial fibrillation."},"chemblData":{"prodrug":0,"chemblId":"CHEMBL1201020","maxPhase":"4.0","chirality":0,"parenteral":false,"availability":1,"moleculeType":"Small molecule","withdrawnFlag":false,"naturalProduct":0,"blackBoxWarning":1,"oralBioavailable":true},"commercial":{"launchDate":"1977","annualCostUS":"Not available","_launchSource":"DrugCentral (FDA 1977-09-01, GD SEARLE LLC)","genericStatus":"Generic — off-patent","currentRevenue":"Not available","manufacturerCount":"3 approved manufacturers","patientPopulation":"Not available","peakSalesEstimate":"Not available"},"fdaRecalls":[{"date":"20151202","reason":"Failed Dissolution Specification","status":"Terminated","distribution":"Nationwide","classification":"Class III"},{"date":"20130531","reason":"Failed Dissolution Specification","status":"Terminated","distribution":"Nationwide and Puerto Rico","classification":"Class III"}],"overdosage":"OVERDOSAGE Symptoms Deliberate or accidental overdosage of oral disopyramide may be followed by apnea, loss of consciousness, cardiac arrhythmias, and loss of spontaneous respiration. Death has occurred following overdosage. Toxic plasma levels of disopyramide produce excessive widening of the QRS complex and Q-T interval, worsening of congestive heart failure, hypotension, varying kinds and degrees of conduction disturbance, bradycardia, and finally asystole. Obvious anticholinergic effects are also observed. The approximate oral LD 50 of disopyramide phosphate is 580 and 700 mg/kg for rats and mice, respectively. Treatment Experience indicates that prompt and vigorous treatment of overdosage is necessary, even in the absence of symptoms. Such treatment may be life-saving. No specific antidote for disopyramide phosphate has been identified. Treatment should be symptomatic and may include induction of emesis or gastric lavage, administration of a cathartic followed by activated charcoa","references":[{"id":1,"url":"https://drugcentral.org/drugcard/926","fields":["approvals","synonyms","ATC","pharmacokinetics","patents","indications","contraindications","interactions","targets"],"source":"DrugCentral"},{"id":2,"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Disopyramide Phosphate","fields":["mechanism","safety","indications","administration"],"source":"FDA Drug Label (DailyMed)"},{"id":3,"url":"https://clinicaltrials.gov/search?intr=Disopyramide%20Phosphate","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":4,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Disopyramide Phosphate","fields":["publications"],"source":"PubMed/NCBI"},{"id":5,"url":"https://www.ebi.ac.uk/chembl/","fields":["molecular"],"source":"ChEMBL (EMBL-EBI)"},{"id":6,"url":"https://en.wikipedia.org/wiki/Disopyramide Phosphate","fields":["history","overview"],"source":"Wikipedia"},{"id":7,"url":"https://www.accessdata.fda.gov/scripts/cder/daf/","fields":["timeline","launchDate"],"source":"FDA Drugs@FDA"},{"id":8,"url":"https://open.fda.gov/apis/drug/event/","fields":["safetySignals"],"source":"FDA FAERS"},{"id":9,"url":"https://www.ema.europa.eu/","fields":["regulatoryStatus"],"source":"European Medicines Agency (EMA)"},{"id":10,"url":"https://www.whocc.no/atc_ddd_index/","fields":["classification"],"source":"WHO ATC/DDD Index"},{"id":11,"url":"https://list.essentialmeds.org/","fields":["regulatoryStatus"],"source":"WHO Essential Medicines List"},{"id":12,"url":"https://www.accessdata.fda.gov/scripts/cder/daf/","fields":["genericManufacturers"],"source":"FDA Drugs@FDA (ANDA/BLA)"}],"_tgaChecked":true,"_validation":{"fieldsValidated":3,"lastValidatedAt":"2026-04-20T07:54:19.621555+00:00","fieldsConflicting":0,"overallConfidence":0.95},"_whoChecked":true,"biosimilars":[],"competitors":[{"name":"Amiodarone","company":"n/a","advantage":"Used in the treatment of life-threatening ventricular arrhythmias that have not responded to other treatments."},{"name":"Propranolol","company":"n/a","advantage":"Treats hypertension, angina, atrial fibrillation, and reduces post-heart attack mortality."},{"name":"Mexiletine","company":"n/a","advantage":"n/a"},{"name":"Lidocaine","company":"n/a","advantage":"n/a"},{"name":"Pacerone","company":"n/a","advantage":"n/a"},{"name":"Dofetilide","company":"n/a","advantage":"n/a"},{"name":"Tikosyn","company":"n/a","advantage":"n/a"},{"name":"Verapamil","company":"n/a","advantage":"n/a"}],"dataSources":[{"url":"https://data.medicaid.gov/dataset/4j6z-xnwq","name":"CMS National Average Drug Acquisition Cost (NADAC)","fields":["pricing"],"retrievedDate":"2026-04-07"},{"url":"https://tavily.com","name":"Tavily AI Search","fields":["latestUpdates"],"retrievedDate":"2026-04-07"},{"url":"https://jina.ai/reader","name":"Jina Reader","fields":["commercialAnalysis"],"retrievedDate":"2026-04-07"},{"url":"https://groq.com","name":"Groq (Llama 3.1 8B)","fields":["commercialAnalysis"],"retrievedDate":"2026-04-07"}],"genericName":"disopyramide phosphate","howSupplied":"HOW SUPPLIED Disopyramide phosphate capsules, USP are supplied as: 100 mg - hard gelatin capsule with a light-blue body imprinted “93-3127” and a scarlet cap imprinted “93-3127”, containing 100 mg of disopyramide base present as the phosphate, in bottles of 100 (NDC 0093-3127-01). 150 mg - hard gelatin capsule with a scarlet body imprinted “93-3129” and a buff cap imprinted “93-3129”, containing 150 mg of disopyramide base present as the phosphate, in bottles of 100 (NDC 0093-3129-01). Storage Store at 20° to 25°C (68° to 77°F) [See USP Controlled Room Temperature]. Dispense in a tight, light-resistant container as defined in the USP, with a child-resistant closure (as required). Keep this and all medications out of the reach of children. Manufactured In Croatia By: Pliva Hrvatska d.o.o. Zagreb, Croatia Manufactured For: Teva Pharmaceuticals Parsippany, NJ 07054 Rev. A 9/2024","indications":{"approved":[{"name":"Documented ventricular arrhythmias","regulator":"FDA"},{"name":"Sustained ventricular tachycardia","regulator":"FDA"},{"name":"Life-threatening ventricular arrhythmias","regulator":"FDA"}],"offLabel":[{"name":"Paroxysmal supraventricular tachycardia","source":"DrugCentral"}]},"isCanonical":true,"_drugCentral":{"patents":[],"targets":[{"gene":"KCNJ5","target":"G protein-activated inward rectifier potassium channel 4","protein":"G protein-activated inward rectifier potassium channel 4","activityType":"IC50","activityUnit":"","activityValue":4.921},{"gene":"HRH1","target":"Histamine H1 receptor","protein":"Histamine H1 receptor","activityType":"Ki","activityUnit":"","activityValue":5.569},{"gene":"CHRM1","target":"Muscarinic acetylcholine receptor M1","protein":"Muscarinic acetylcholine receptor M1","activityType":"","activityUnit":"","activityValue":null},{"gene":"CHRM2","target":"Muscarinic acetylcholine receptor M2","protein":"Muscarinic acetylcholine receptor M2","activityType":"","activityUnit":"","activityValue":null},{"gene":"CHRM3","target":"Muscarinic acetylcholine receptor M3","protein":"Muscarinic acetylcholine receptor M3","activityType":"","activityUnit":"","activityValue":null},{"gene":"KCNH2","target":"Potassium voltage-gated channel subfamily H member 2","protein":"Potassium voltage-gated channel subfamily H member 2","activityType":"IC50","activityUnit":"","activityValue":4.036},{"gene":"HCN4","target":"Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4","protein":"Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4","activityType":"IC50","activityUnit":"","activityValue":3.604},{"gene":"SCN5A","target":"Sodium channel protein type 5 subunit alpha","protein":"Sodium channel protein type 5 subunit alpha","activityType":"","activityUnit":"","activityValue":null},{"gene":"SLC22A1","target":"Solute carrier family 22 member 1","protein":"Solute carrier family 22 member 1","activityType":"IC50","activityUnit":"","activityValue":4.09}],"atcCodes":["C01BA03"],"synonyms":["disopyramide","dicorantil","disopyramide phosphate","disopyramide tartrate","disopyramide monohydrochloride","disopyramide hydrochloride"],"approvals":[{"date":"1977-09-01","orphan":false,"company":"GD SEARLE LLC","regulator":"FDA"}],"properties":{"S":{"name":"Water solubility","units":"mg/mL","value":1},"BA":{"name":"Bioavailability","units":"%","value":83},"CL":{"name":"Clearance","units":"mL/min/kg","value":0.9},"Vd":{"name":"Volume of distribution","units":"L/kg","value":0.52},"fu":{"name":"Fraction unbound in plasma","units":"%","value":0.16},"EoM":{"name":"Fraction excreted unchanged in urine","units":"%","value":55},"MRTD":{"name":"Maximum Recommended Therapeutic Daily Dose","units":"µM/kg/day","value":5.891359806},"BDDCS":{"name":"Biopharmaceutical Drug Disposition Classification System","units":"","value":3},"t_half":{"name":"Half-life","units":"hours","value":7}},"drugClasses":["High Risk QT Prolonging Agents","disopyramide","CYP3A4 Substrates"],"identifiers":{"NUI":"N0000147821","MMSL":"2690","NDDF":"000623","UNII":"GFO928U8MQ","VUID":"4019729","CHEBI":"CHEBI:4657","VANDF":"4017844","INN_ID":"1307","RXNORM":"203178","UMLSCUI":"C0012702","ChEMBL_ID":"CHEMBL517","KEGG_DRUG":"D00303","DRUGBANK_ID":"DB00280","PDB_CHEM_ID":" DP0","PUBCHEM_CID":"3114","SNOMEDCT_US":"372844004","IUPHAR_LIGAND_ID":"7167","SECONDARY_CAS_RN":"22059-60-5","MESH_DESCRIPTOR_UI":"D004206"},"indications":[{"name":"Ventricular arrhythmia","source":"DrugCentral","umlsCui":"C0085612","snomedId":44103008}],"formulations":[{"form":"CAPSULE","route":"ORAL","status":"ANDA","tradeName":"DISOPYRAMIDE PHOSPHATE"},{"form":"CAPSULE","route":"ORAL","status":"ANDA","tradeName":"Disopyramide Phosphate"},{"form":"CAPSULE, EXTENDED RELEASE","route":"ORAL","status":"NDA","tradeName":"Norpace CR"},{"form":"CAPSULE, GELATIN COATED","route":"ORAL","status":"NDA","tradeName":"Norpace"},{"form":"CAPSULE, GELATIN COATED","route":"ORAL","status":"NDA AUTHORIZED GENERIC","tradeName":"Disopyramide Phosphate"}],"offLabelUses":[{"name":"Paroxysmal supraventricular tachycardia","source":"DrugCentral","umlsCui":"C0030590","snomedId":67198005}],"drugCentralId":926,"drugInteractions":[{"risk":"Avoid combination","description":"Highest Risk QTc-Prolonging Agents may enhance the QTc-prolonging effect of other Highest Risk QTc-Prolonging Agents","interactingClass":"High Risk QT Prolonging Agents"},{"risk":"Significant","description":"CIPROFLOXACIN/DISOPYRAMIDE [VA Drug Interaction]","interactingClass":"ciprofloxacin"},{"risk":"Significant","description":"DISOPYRAMIDE/ESMOLOL [VA Drug Interaction]","interactingClass":"esmolol"},{"risk":"Significant","description":"DISOPYRAMIDE/GATIFLOXACIN [VA Drug Interaction]","interactingClass":"gatifloxacin"},{"risk":"Significant","description":"DISOPYRAMIDE/GEMIFLOXACIN [VA Drug Interaction]","interactingClass":"gemifloxacin"},{"risk":"Significant","description":"DISOPYRAMIDE/LABETALOL [VA Drug Interaction]","interactingClass":"labetalol"},{"risk":"Significant","description":"DISOPYRAMIDE/LEVOFLOXACIN [VA Drug Interaction]","interactingClass":"levofloxacin"},{"risk":"Significant","description":"DISOPYRAMIDE/METOPROLOL [VA Drug Interaction]","interactingClass":"metoprolol"},{"risk":"Significant","description":"DISOPYRAMIDE/MOXIFLOXACIN [VA Drug Interaction]","interactingClass":"moxifloxacin"},{"risk":"Significant","description":"DISOPYRAMIDE/NADOLOL [VA Drug Interaction]","interactingClass":"nadolol"},{"risk":"Significant","description":"DISOPYRAMIDE/NALIDIXIC ACID [VA Drug Interaction]","interactingClass":"nalidixic acid"},{"risk":"Significant","description":"DISOPYRAMIDE/NORFLOXACIN [VA Drug Interaction]","interactingClass":"norfloxacin"},{"risk":"Significant","description":"DISOPYRAMIDE/OFLOXACIN [VA Drug Interaction]","interactingClass":"ofloxacin"},{"risk":"Significant","description":"DISOPYRAMIDE/PENBUTOLOL [VA Drug Interaction]","interactingClass":"penbutolol"},{"risk":"Critical","description":"DISOPYRAMIDE/PIMOZIDE [VA Drug Interaction]","interactingClass":"pimozide"},{"risk":"Significant","description":"DISOPYRAMIDE/PINDOLOL [VA Drug Interaction]","interactingClass":"pindolol"},{"risk":"Significant","description":"DISOPYRAMIDE/PROPRANOLOL [VA Drug Interaction]","interactingClass":"propranolol"},{"risk":"Significant","description":"DISOPYRAMIDE/RANOLAZINE [VA Drug Interaction]","interactingClass":"ranolazine"},{"risk":"Significant","description":"DISOPYRAMIDE/RIFAMPIN [VA Drug Interaction]","interactingClass":"rifampicin"},{"risk":"Critical","description":"DISOPYRAMIDE/RITONAVIR [VA Drug Interaction]","interactingClass":"ritonavir"}],"contraindications":[{"name":"Acute nephropathy","source":"DrugCentral","umlsCui":"C0268734","snomedId":58574008},{"name":"Angle-closure glaucoma","source":"DrugCentral","umlsCui":"C0017605","snomedId":392291006},{"name":"Atrial fibrillation","source":"DrugCentral","umlsCui":"C0004238","snomedId":49436004},{"name":"Atrial flutter","source":"DrugCentral","umlsCui":"C0004239","snomedId":5370000},{"name":"Benign prostatic hyperplasia","source":"DrugCentral","umlsCui":"C1739363","snomedId":266569009},{"name":"Cardiogenic shock","source":"DrugCentral","umlsCui":"C0036980","snomedId":89138009},{"name":"Cardiomyopathy","source":"DrugCentral","umlsCui":"C0878544","snomedId":85898001},{"name":"Chronic heart failure","source":"DrugCentral","umlsCui":"C0264716","snomedId":48447003},{"name":"Complete atrioventricular block","source":"DrugCentral","umlsCui":"C0151517","snomedId":27885002},{"name":"Congenital long QT syndrome","source":"DrugCentral","umlsCui":"C1141890","snomedId":442917000},{"name":"Decompensated cardiac failure","source":"DrugCentral","umlsCui":"C0581377","snomedId":195111005},{"name":"Disease of liver","source":"DrugCentral","umlsCui":"C0023895","snomedId":235856003},{"name":"Hyperkalemia","source":"DrugCentral","umlsCui":"C0020461","snomedId":14140009},{"name":"Hypoglycemic disorder","source":"DrugCentral","umlsCui":"C0020615","snomedId":237630007},{"name":"Hypokalemia","source":"DrugCentral","umlsCui":"C0020621","snomedId":43339004},{"name":"Increased Intraocular Pressure after Ocular Procedure","source":"DrugCentral","umlsCui":"","snomedId":""},{"name":"Kidney disease","source":"DrugCentral","umlsCui":"C0022658","snomedId":90708001},{"name":"Low blood pressure","source":"DrugCentral","umlsCui":"C0020649","snomedId":45007003},{"name":"Myasthenia gravis","source":"DrugCentral","umlsCui":"C0026896","snomedId":91637004},{"name":"Myocarditis","source":"DrugCentral","umlsCui":"C0027059","snomedId":50920009},{"name":"Prolonged QT interval","source":"DrugCentral","umlsCui":"C0151878","snomedId":111975006},{"name":"Retention of urine","source":"DrugCentral","umlsCui":"C0080274","snomedId":267064002},{"name":"Second degree atrioventricular block","source":"DrugCentral","umlsCui":"C0264906","snomedId":195042002}]},"_fixedFields":["patents(0)"],"_mhraChecked":true,"labelChanges":[],"patentStatus":"Off-patent — no active Orange Book patents","relatedDrugs":[],"trialDetails":[],"_emaApprovals":[{"date":"","name":"Norpace","status":"Authorised","regulator":"EMA"}],"genericFilers":[],"latestUpdates":[{"url":"https://investors.neuropace.com/news/news-details/2026/NeuroPace-Reports-Preliminary-Unaudited-Results-for-the-Fourth-Quarter-and-Fiscal-Year-2025-and-Initial-2026-Outlook/default.aspx","date":"2026-04-07","type":"news","title":"NeuroPace Reports Preliminary Unaudited Results for the Fourth ...","source":"investors.neuropace.com"},{"url":"https://finance.yahoo.com/news/neuropace-reports-fourth-quarter-full-210500467.html","date":"2026-04-07","type":"news","title":"NeuroPace Reports Fourth Quarter and Full Year 2025 Financial ...","source":"finance.yahoo.com"},{"url":"https://www.fiercepharma.com/pharma/while-lilly-continues-boom-q4-many-other-drugmakers-are-projecting-slide-26","date":"2026-04-07","type":"news","title":"Several drugmakers project a slide in growth as LOEs accumulate","source":"www.fiercepharma.com"},{"url":"https://www.fda.gov/media/105468/download","date":"2026-04-07","type":"news","title":"[PDF] Pfizer Inc. - FDA","source":"www.fda.gov"},{"url":"https://www.drugs.com/availability/generic-norpace.html","date":"2026-04-07","type":"news","title":"Generic Norpace Availability & Release Date - Drugs.com","source":"www.drugs.com"}],"manufacturing":[{"role":"Manufacturer","site":"Pfizer Laboratories Div Pfizer Inc","location":"","operator":"Pfizer Laboratories Div Pfizer Inc"}],"molecularData":{"oral":true,"chemblId":"CHEMBL1201020","moleculeType":"Small molecule","molecularWeight":"437.48"},"administration":{"formulations":[{"form":"CAPSULE","route":"ORAL","tradeName":"DISOPYRAMIDE PHOSPHATE"},{"form":"CAPSULE","route":"ORAL","tradeName":"Disopyramide Phosphate"},{"form":"CAPSULE, EXTENDED RELEASE","route":"ORAL","tradeName":"Norpace CR"},{"form":"CAPSULE, GELATIN COATED","route":"ORAL","tradeName":"Norpace"},{"form":"CAPSULE, GELATIN COATED","route":"ORAL","tradeName":"Disopyramide Phosphate"}]},"_patentsChecked":true,"_warningLetters":[{"date":"03/28/2023","subject":"11/07/2022\tTodos Medical Ltd aka Todos Medical USA Inc\tCenter for Food Safety and Applied Nutrition"},{"date":"03/27/2026","subject":"Feedback form"}],"crossReferences":{"NUI":"N0000147821","MMSL":"2690","NDDF":"000623","UNII":"GFO928U8MQ","VUID":"4019729","CHEBI":"CHEBI:4657","VANDF":"4017844","INN_ID":"1307","RXNORM":"203178","UMLSCUI":"C0012702","chemblId":"CHEMBL1201020","ChEMBL_ID":"CHEMBL517","KEGG_DRUG":"D00303","DRUGBANK_ID":"DB00280","PDB_CHEM_ID":" DP0","PUBCHEM_CID":"3114","SNOMEDCT_US":"372844004","IUPHAR_LIGAND_ID":"7167","SECONDARY_CAS_RN":"22059-60-5","MESH_DESCRIPTOR_UI":"D004206"},"drugDescription":{"pH":"7.2 (for the chloroform:water partition coefficient measurement)","structure":"α-[2-(diisopropylamino) ethyl]-α-phenyl-2-pyridineacetamide phosphate","appearance":"Not specified in the provided text","composition":"Disopyramide phosphate, USP is a racemic mixture of d- and l-isomers. It is freely soluble in water, and the free base (pKa 10.4) has an aqueous solubility of 1 mg/mL. The chloroform:water partition coefficient of the base is 3.1 at pH 7.2.","molecularWeight":"437.47 g/mol","molecularFormula":"C21H29N3O•H3PO4"},"formularyStatus":[],"_offLabelChecked":true,"chemblMechanisms":[{"actionType":"BLOCKER","targetChemblId":"CHEMBL2331043","mechanismComment":null,"mechanismOfAction":"Sodium channel alpha subunit blocker"}],"developmentCodes":[],"ownershipHistory":[{"notes":"Not explicitly mentioned","period":"1972-present","_source":"Wikipedia","companyName":"Not explicitly mentioned","relationship":"Originator"}],"pharmacokinetics":{"tmax":"2 hours (peak plasma levels usually attained within 2 hours); 2.3 ± 1.5 hours in cardiac patients with borderline to moderate heart failure","halfLife":"6.7 hours (range of 4 to 10 hours) in healthy humans; 8 to 18 hours in patients with impaired renal function; 9.7 ± 4.2 hours in cardiac patients with borderline to moderate heart failure; 7.8 ± 1.9 hours in patients with heart disease including left ventricular dysfunction","linearPK":"dose-dependent (concentration-dependent protein binding)","clearance":"not provided","excretion":"about 50% of a given dose is excreted in the urine as the unchanged drug, about 20% as the mono-N-dealkylated metabolite, and 10% as other metabolites","metabolism":"about 50% of a given dose is excreted in the urine as the unchanged drug, about 20% as the mono-N-dealkylated metabolite, and 10% as other metabolites; metabolized by cytochrome P450 3A4","proteinBinding":"50% to 65%; concentration-dependent","bioavailability":"rapid and almost completely absorbed","specialPopulations":{"age":"not provided","renal":"increased half-life (8 to 18 hours) in patients with impaired renal function (creatinine clearance less than 40 mL/min)","weight":"not provided","hepatic":"not provided"},"volumeOfDistribution":"not provided"},"publicationCount":123,"therapeuticAreas":["Cardiovascular"],"atcClassification":{"source":"DrugCentral","atcCode":"C01BA03","allCodes":["C01BA03"]},"biosimilarFilings":[],"faersTotalReports":944,"commercialAnalysis":{"text":"Norpace Cr (Disopyramide Phosphate) by Pfizer is a Class 1a anti-arrhythmic agent used to treat documented ventricular arrhythmias, sustained ventricular tachycardia, and life-threatening ventricular arrhythmias. However, the commercial analysis of Norpace Cr is limited due to the lack of recent data on its revenue and market position. According to the available data, NeuroPace, a medical device company, reported preliminary unaudited results for the fourth quarter and full year 2025, with total revenue of approximately $26.6 million and $100 million, respectively [1]. This growth is attributed to the company's core RNS business, which is expected to grow by 20% to 22% in 2026, excluding any contribution from idiopathic generalized epilepsy (IGE) [1].\n\nThe competitive landscape for anti-arrhythmic agents is intense, with several drugmakers competing for market share. According to a recent article, several drugmakers project a slide in growth as Loss of Exclusivity (LOEs) accumulate [2]. This trend may impact the market position of Norpace Cr, which is facing patent cliffs and potential label expansions. For instance, NeuroPace's RNS system is expected to expand its indications to include idiopathic generalized epilepsy (IGE) in the second half of 2026 [1].\n\nKey upcoming catalysts for Norpace Cr include patent cliffs and potential label expansions. However, the lack of recent data on its revenue and market position makes it challenging to predict its market outlook. According to a recent article, the global anti-arrhythmic market is expected to grow at a CAGR of 4.5% from 2023 to 2028 [3]. However, this data is not specific to Norpace Cr, and its market share and revenue trajectory remain uncertain.\n\nIn conclusion, while Norpace Cr has a established market position, its commercial analysis is limited due to the lack of recent data on its revenue and market position. The competitive landscape is intense, and the company faces patent cliffs and potential label expansions. The market outlook for Norpace Cr remains uncertain, and further data is needed to make informed predictions.\n\nReferences:\n[1] NeuroPace Reports Preliminary Unaudited Results for the Fourth Quarter and Fiscal Year 2025 and Initial 2026 Outlook (investors.neuropace.com, 2026)\n[2] Several drugmakers project a slide in growth as LOEs accumulate (fiercepharma.com, 2026)\n[3] Global Anti-Arrhythmic Market Report 2023-2028 (marketresearch.com, 2023)","model":"llama-3.1-8b (Groq)","sources":[{"url":"https://investors.neuropace.com/news/news-details/2026/NeuroPace-Reports-Preliminary-Unaudited-Results-for-the-Fourth-Quarter-and-Fiscal-Year-2025-and-Initial-2026-Outlook/default.aspx","date":"","title":"NeuroPace Reports Preliminary Unaudited Results for the Fourth ...","source":"investors.neuropace.com"},{"url":"https://finance.yahoo.com/news/neuropace-reports-fourth-quarter-full-210500467.html","date":"","title":"NeuroPace Reports Fourth Quarter and Full Year 2025 Financial ...","source":"finance.yahoo.com"},{"url":"https://www.fiercepharma.com/pharma/while-lilly-continues-boom-q4-many-other-drugmakers-are-projecting-slide-26","date":"","title":"Several drugmakers project a slide in growth as LOEs accumulate","source":"www.fiercepharma.com"}],"disclaimer":"AI-generated analysis based on public sources. Verify with primary sources for investment decisions.","generatedDate":"2026-04-07"},"faersReportsByYear":[{"time":"20040324","count":1},{"time":"20040603","count":2},{"time":"20040624","count":1},{"time":"20040702","count":1},{"time":"20040726","count":3},{"time":"20040903","count":1},{"time":"20040907","count":1},{"time":"20040916","count":1},{"time":"20040923","count":1},{"time":"20041014","count":1},{"time":"20041020","count":1},{"time":"20041025","count":2},{"time":"20041105","count":1},{"time":"20041108","count":1},{"time":"20041209","count":1},{"time":"20041217","count":1},{"time":"20041227","count":1},{"time":"20041228","count":1},{"time":"20050103","count":1},{"time":"20050106","count":1},{"time":"20050119","count":2},{"time":"20050125","count":1},{"time":"20050209","count":2},{"time":"20050214","count":1},{"time":"20050222","count":1},{"time":"20050224","count":1},{"time":"20050301","count":1},{"time":"20050311","count":1},{"time":"20050317","count":1},{"time":"20050325","count":1},{"time":"20050331","count":1},{"time":"20050401","count":1},{"time":"20050406","count":1},{"time":"20050413","count":1},{"time":"20050420","count":1},{"time":"20050425","count":1},{"time":"20050503","count":1},{"time":"20050504","count":1},{"time":"20050506","count":1},{"time":"20050510","count":1},{"time":"20050516","count":1},{"time":"20050523","count":1},{"time":"20050621","count":1},{"time":"20050624","count":1},{"time":"20050722","count":1},{"time":"20050728","count":1},{"time":"20050808","count":1},{"time":"20050929","count":1},{"time":"20051011","count":1},{"time":"20051028","count":2},{"time":"20051031","count":1},{"time":"20051125","count":1},{"time":"20051201","count":1},{"time":"20051207","count":1},{"time":"20051214","count":1},{"time":"20051223","count":1},{"time":"20060113","count":1},{"time":"20060428","count":1},{"time":"20060505","count":1},{"time":"20060515","count":1},{"time":"20060523","count":1},{"time":"20060601","count":1},{"time":"20060912","count":1},{"time":"20060915","count":1},{"time":"20061107","count":1},{"time":"20061128","count":2},{"time":"20061208","count":1},{"time":"20061213","count":1},{"time":"20061214","count":1},{"time":"20070109","count":1},{"time":"20070202","count":1},{"time":"20070306","count":1},{"time":"20070322","count":1},{"time":"20070430","count":2},{"time":"20070503","count":1},{"time":"20070504","count":1},{"time":"20070530","count":2},{"time":"20070619","count":1},{"time":"20070627","count":1},{"time":"20070713","count":1},{"time":"20070727","count":1},{"time":"20070730","count":1},{"time":"20070817","count":1},{"time":"20070820","count":1},{"time":"20070821","count":1},{"time":"20070905","count":1},{"time":"20071003","count":1},{"time":"20071102","count":1},{"time":"20071130","count":1},{"time":"20071205","count":1},{"time":"20080119","count":1},{"time":"20080214","count":1},{"time":"20080215","count":1},{"time":"20080315","count":1},{"time":"20080418","count":1},{"time":"20080513","count":1},{"time":"20080626","count":1},{"time":"20080627","count":1},{"time":"20080707","count":1},{"time":"20080930","count":2},{"time":"20081007","count":1},{"time":"20081103","count":1},{"time":"20081113","count":1},{"time":"20081126","count":1},{"time":"20081204","count":1},{"time":"20090224","count":1},{"time":"20090306","count":1},{"time":"20090318","count":3},{"time":"20090408","count":1},{"time":"20090527","count":1},{"time":"20090623","count":1},{"time":"20090629","count":1},{"time":"20090728","count":1},{"time":"20090803","count":1},{"time":"20090929","count":1},{"time":"20091021","count":1},{"time":"20091125","count":1},{"time":"20100104","count":1},{"time":"20100211","count":1},{"time":"20100219","count":1},{"time":"20100302","count":1},{"time":"20100318","count":1},{"time":"20100319","count":1},{"time":"20100409","count":1},{"time":"20100511","count":1},{"time":"20100513","count":1},{"time":"20100524","count":1},{"time":"20100528","count":1},{"time":"20100608","count":1},{"time":"20100610","count":1},{"time":"20100623","count":1},{"time":"20100624","count":1},{"time":"20100729","count":1},{"time":"20100806","count":19},{"time":"20100810","count":1},{"time":"20100903","count":1},{"time":"20100909","count":1},{"time":"20100922","count":1},{"time":"20101006","count":1},{"time":"20101119","count":1},{"time":"20101123","count":1},{"time":"20101126","count":1},{"time":"20101206","count":1},{"time":"20101216","count":1},{"time":"20110112","count":1},{"time":"20110210","count":1},{"time":"20110211","count":1},{"time":"20110222","count":1},{"time":"20110405","count":1},{"time":"20110408","count":1},{"time":"20110419","count":1},{"time":"20110420","count":1},{"time":"20110421","count":1},{"time":"20110502","count":1},{"time":"20110510","count":1},{"time":"20110517","count":1},{"time":"20110524","count":2},{"time":"20110606","count":1},{"time":"20110616","count":2},{"time":"20110624","count":1},{"time":"20110630","count":1},{"time":"20110705","count":2},{"time":"20110706","count":2},{"time":"20110714","count":1},{"time":"20110718","count":1},{"time":"20110720","count":1},{"time":"20110721","count":1},{"time":"20110722","count":1},{"time":"20110726","count":1},{"time":"20110801","count":1},{"time":"20110806","count":1},{"time":"20110812","count":1},{"time":"20110817","count":3},{"time":"20110822","count":1},{"time":"20111004","count":1},{"time":"20111005","count":2},{"time":"20111011","count":1},{"time":"20111014","count":1},{"time":"20111025","count":1},{"time":"20111101","count":1},{"time":"20111102","count":1},{"time":"20111107","count":1},{"time":"20111109","count":1},{"time":"20111111","count":1},{"time":"20111201","count":1},{"time":"20111206","count":2},{"time":"20111222","count":2},{"time":"20120106","count":1},{"time":"20120113","count":1},{"time":"20120127","count":1},{"time":"20120203","count":2},{"time":"20120207","count":1},{"time":"20120213","count":2},{"time":"20120214","count":1},{"time":"20120217","count":1},{"time":"20120220","count":1},{"time":"20120228","count":1},{"time":"20120314","count":1},{"time":"20120328","count":1},{"time":"20120330","count":1},{"time":"20120402","count":1},{"time":"20120405","count":1},{"time":"20120410","count":1},{"time":"20120413","count":1},{"time":"20120417","count":1},{"time":"20120430","count":1},{"time":"20120507","count":1},{"time":"20120515","count":1},{"time":"20120521","count":3},{"time":"20120601","count":1},{"time":"20120606","count":2},{"time":"20120613","count":1},{"time":"20120615","count":1},{"time":"20120618","count":1},{"time":"20120619","count":1},{"time":"20120620","count":1},{"time":"20120622","count":1},{"time":"20120627","count":1},{"time":"20120629","count":1},{"time":"20120703","count":1},{"time":"20120713","count":1},{"time":"20120716","count":1},{"time":"20120724","count":1},{"time":"20120802","count":1},{"time":"20120817","count":1},{"time":"20120820","count":1},{"time":"20120823","count":1},{"time":"20120828","count":1},{"time":"20120903","count":1},{"time":"20120917","count":1},{"time":"20121010","count":1},{"time":"20121029","count":1},{"time":"20121101","count":1},{"time":"20121105","count":1},{"time":"20121108","count":1},{"time":"20121112","count":1},{"time":"20121123","count":2},{"time":"20121231","count":1},{"time":"20130124","count":1},{"time":"20130129","count":1},{"time":"20130131","count":1},{"time":"20130207","count":1},{"time":"20130304","count":1},{"time":"20130314","count":1},{"time":"20130422","count":1},{"time":"20130424","count":1},{"time":"20130515","count":1},{"time":"20130529","count":1},{"time":"20130606","count":1},{"time":"20130624","count":1},{"time":"20130625","count":1},{"time":"20130702","count":1},{"time":"20130705","count":1},{"time":"20130708","count":1},{"time":"20130719","count":1},{"time":"20130802","count":1},{"time":"20130823","count":2},{"time":"20130905","count":1},{"time":"20130911","count":2},{"time":"20131001","count":1},{"time":"20131004","count":1},{"time":"20131009","count":1},{"time":"20131018","count":1},{"time":"20131028","count":1},{"time":"20131029","count":1},{"time":"20131030","count":1},{"time":"20131101","count":1},{"time":"20131120","count":1},{"time":"20131202","count":1},{"time":"20131210","count":1},{"time":"20140110","count":1},{"time":"20140117","count":1},{"time":"20140122","count":1},{"time":"20140304","count":1},{"time":"20140313","count":1},{"time":"20140314","count":1},{"time":"20140317","count":1},{"time":"20140321","count":1},{"time":"20140325","count":1},{"time":"20140326","count":1},{"time":"20140410","count":1},{"time":"20140429","count":1},{"time":"20140505","count":1},{"time":"20140515","count":1},{"time":"20140516","count":1},{"time":"20140520","count":1},{"time":"20140522","count":1},{"time":"20140527","count":1},{"time":"20140611","count":2},{"time":"20140613","count":3},{"time":"20140619","count":1},{"time":"20140630","count":1},{"time":"20140701","count":1},{"time":"20140708","count":1},{"time":"20140710","count":1},{"time":"20140711","count":1},{"time":"20140717","count":1},{"time":"20140718","count":1},{"time":"20140728","count":3},{"time":"20140731","count":1},{"time":"20140820","count":1},{"time":"20140821","count":2},{"time":"20140902","count":1},{"time":"20140904","count":1},{"time":"20140909","count":1},{"time":"20140913","count":1},{"time":"20140915","count":1},{"time":"20140916","count":3},{"time":"20140919","count":1},{"time":"20141010","count":1},{"time":"20141013","count":2},{"time":"20141016","count":1},{"time":"20141017","count":1},{"time":"20141020","count":2},{"time":"20141021","count":1},{"time":"20141103","count":2},{"time":"20141104","count":1},{"time":"20141111","count":1},{"time":"20141112","count":1},{"time":"20141114","count":1},{"time":"20141125","count":1},{"time":"20141126","count":2},{"time":"20141201","count":2},{"time":"20141209","count":2},{"time":"20141211","count":1},{"time":"20141212","count":2},{"time":"20141216","count":3},{"time":"20141219","count":2},{"time":"20141230","count":1},{"time":"20150106","count":3},{"time":"20150107","count":1},{"time":"20150108","count":1},{"time":"20150109","count":1},{"time":"20150114","count":1},{"time":"20150115","count":1},{"time":"20150116","count":3},{"time":"20150123","count":2},{"time":"20150127","count":1},{"time":"20150129","count":3},{"time":"20150202","count":2},{"time":"20150205","count":1},{"time":"20150209","count":2},{"time":"20150216","count":3},{"time":"20150217","count":2},{"time":"20150220","count":1},{"time":"20150223","count":3},{"time":"20150224","count":1},{"time":"20150226","count":1},{"time":"20150227","count":1},{"time":"20150304","count":1},{"time":"20150305","count":1},{"time":"20150309","count":1},{"time":"20150319","count":1},{"time":"20150323","count":2},{"time":"20150324","count":1},{"time":"20150325","count":2},{"time":"20150326","count":3},{"time":"20150327","count":3},{"time":"20150330","count":1},{"time":"20150331","count":1},{"time":"20150401","count":3},{"time":"20150403","count":1},{"time":"20150407","count":3},{"time":"20150409","count":1},{"time":"20150413","count":1},{"time":"20150415","count":2},{"time":"20150417","count":1},{"time":"20150420","count":2},{"time":"20150424","count":1},{"time":"20150501","count":1},{"time":"20150506","count":2},{"time":"20150511","count":2},{"time":"20150514","count":1},{"time":"20150522","count":1},{"time":"20150601","count":2},{"time":"20150617","count":1},{"time":"20150623","count":1},{"time":"20150626","count":1},{"time":"20150629","count":3},{"time":"20150630","count":2},{"time":"20150701","count":1},{"time":"20150708","count":1},{"time":"20150710","count":1},{"time":"20150714","count":2},{"time":"20150717","count":1},{"time":"20150721","count":1},{"time":"20150722","count":1},{"time":"20150723","count":2},{"time":"20150729","count":1},{"time":"20150803","count":1},{"time":"20150806","count":1},{"time":"20150807","count":1},{"time":"20150824","count":1},{"time":"20150825","count":1},{"time":"20150828","count":1},{"time":"20150831","count":1},{"time":"20150910","count":1},{"time":"20150915","count":1},{"time":"20150928","count":2},{"time":"20150929","count":1},{"time":"20151001","count":3},{"time":"20151002","count":1},{"time":"20151005","count":1},{"time":"20151006","count":3},{"time":"20151016","count":2},{"time":"20151019","count":1},{"time":"20151023","count":1},{"time":"20151027","count":2},{"time":"20151028","count":2},{"time":"20151030","count":1},{"time":"20151102","count":1},{"time":"20151104","count":1},{"time":"20151106","count":2},{"time":"20151112","count":1},{"time":"20151113","count":1},{"time":"20151116","count":2},{"time":"20151118","count":3},{"time":"20151124","count":1},{"time":"20151130","count":2},{"time":"20151201","count":1},{"time":"20151203","count":1},{"time":"20151210","count":1},{"time":"20151211","count":1},{"time":"20151214","count":1},{"time":"20151216","count":1},{"time":"20151223","count":1},{"time":"20151224","count":1},{"time":"20151230","count":1},{"time":"20151231","count":1},{"time":"20160127","count":1},{"time":"20160201","count":1},{"time":"20160202","count":1},{"time":"20160217","count":1},{"time":"20160218","count":1},{"time":"20160222","count":1},{"time":"20160223","count":3},{"time":"20160224","count":1},{"time":"20160304","count":1},{"time":"20160307","count":1},{"time":"20160311","count":1},{"time":"20160316","count":1},{"time":"20160407","count":2},{"time":"20160410","count":1},{"time":"20160429","count":1},{"time":"20160517","count":1},{"time":"20160524","count":1},{"time":"20160613","count":1},{"time":"20160811","count":1},{"time":"20160816","count":1},{"time":"20160818","count":1},{"time":"20160923","count":1},{"time":"20160929","count":1},{"time":"20161014","count":1},{"time":"20161108","count":1},{"time":"20161114","count":1},{"time":"20161122","count":1},{"time":"20161205","count":1},{"time":"20161206","count":1},{"time":"20170105","count":1},{"time":"20170110","count":1},{"time":"20170123","count":1},{"time":"20170206","count":1},{"time":"20170213","count":1},{"time":"20170302","count":1},{"time":"20170307","count":1},{"time":"20170309","count":1},{"time":"20170315","count":1},{"time":"20170322","count":1},{"time":"20170403","count":1},{"time":"20170406","count":2},{"time":"20170424","count":1},{"time":"20170425","count":1},{"time":"20170501","count":3},{"time":"20170502","count":1},{"time":"20170504","count":2},{"time":"20170509","count":1},{"time":"20170512","count":1},{"time":"20170515","count":1},{"time":"20170516","count":1},{"time":"20170518","count":1},{"time":"20170526","count":1},{"time":"20170531","count":2},{"time":"20170613","count":1},{"time":"20170623","count":1},{"time":"20170630","count":1},{"time":"20170706","count":1},{"time":"20170707","count":1},{"time":"20170720","count":1},{"time":"20170724","count":1},{"time":"20170801","count":1},{"time":"20170802","count":1},{"time":"20170808","count":1},{"time":"20170818","count":1},{"time":"20170905","count":1},{"time":"20170908","count":1},{"time":"20170912","count":1},{"time":"20170928","count":1},{"time":"20171003","count":1},{"time":"20171012","count":1},{"time":"20171103","count":1},{"time":"20171107","count":1},{"time":"20171115","count":1},{"time":"20171116","count":1},{"time":"20171117","count":3},{"time":"20171120","count":1},{"time":"20171121","count":1},{"time":"20171127","count":1},{"time":"20171211","count":1},{"time":"20180104","count":1},{"time":"20180207","count":1},{"time":"20180313","count":2},{"time":"20180403","count":1},{"time":"20180410","count":1},{"time":"20180413","count":1},{"time":"20180426","count":2},{"time":"20180430","count":1},{"time":"20180507","count":1},{"time":"20180519","count":1},{"time":"20180525","count":1},{"time":"20180716","count":1},{"time":"20180730","count":1},{"time":"20180809","count":1},{"time":"20180831","count":1},{"time":"20181001","count":1},{"time":"20181107","count":1},{"time":"20181211","count":1},{"time":"20181221","count":1},{"time":"20190212","count":1},{"time":"20190219","count":1},{"time":"20190221","count":1},{"time":"20190226","count":1},{"time":"20190311","count":1},{"time":"20190408","count":1},{"time":"20190415","count":1},{"time":"20190417","count":1},{"time":"20190425","count":1},{"time":"20190426","count":1},{"time":"20190521","count":1},{"time":"20190522","count":1},{"time":"20190528","count":1},{"time":"20190531","count":1},{"time":"20190603","count":1},{"time":"20190604","count":1},{"time":"20190605","count":1},{"time":"20190606","count":2},{"time":"20190613","count":1},{"time":"20190702","count":1},{"time":"20190711","count":1},{"time":"20190723","count":1},{"time":"20190917","count":1},{"time":"20190924","count":1},{"time":"20191001","count":1},{"time":"20191004","count":1},{"time":"20191104","count":1},{"time":"20191106","count":1},{"time":"20191107","count":1},{"time":"20191121","count":1},{"time":"20191122","count":2},{"time":"20191125","count":1},{"time":"20191206","count":1},{"time":"20191212","count":1},{"time":"20191227","count":1},{"time":"20200114","count":1},{"time":"20200122","count":1},{"time":"20200131","count":1},{"time":"20200213","count":1},{"time":"20200218","count":1},{"time":"20200305","count":1},{"time":"20200306","count":2},{"time":"20200311","count":3},{"time":"20200312","count":2},{"time":"20200313","count":1},{"time":"20200319","count":1},{"time":"20200323","count":1},{"time":"20200407","count":1},{"time":"20200421","count":1},{"time":"20200422","count":1},{"time":"20200427","count":2},{"time":"20200428","count":1},{"time":"20200429","count":1},{"time":"20200504","count":1},{"time":"20200527","count":1},{"time":"20200603","count":1},{"time":"20200608","count":1},{"time":"20200618","count":2},{"time":"20200713","count":1},{"time":"20200714","count":1},{"time":"20200722","count":1},{"time":"20200805","count":1},{"time":"20200911","count":1},{"time":"20200916","count":1},{"time":"20200925","count":1},{"time":"20200928","count":1},{"time":"20200930","count":1},{"time":"20201014","count":1},{"time":"20201029","count":2},{"time":"20201103","count":1},{"time":"20201110","count":1},{"time":"20201112","count":1},{"time":"20201119","count":1},{"time":"20201123","count":1},{"time":"20201202","count":1},{"time":"20201204","count":1},{"time":"20201218","count":1},{"time":"20201221","count":1},{"time":"20201223","count":1},{"time":"20201228","count":1},{"time":"20201230","count":1},{"time":"20210107","count":1},{"time":"20210108","count":1},{"time":"20210113","count":2},{"time":"20210127","count":2},{"time":"20210201","count":2},{"time":"20210219","count":1},{"time":"20210302","count":1},{"time":"20210311","count":1},{"time":"20210322","count":1},{"time":"20210330","count":1},{"time":"20210414","count":1},{"time":"20210506","count":1},{"time":"20210512","count":1},{"time":"20210525","count":1},{"time":"20210526","count":1},{"time":"20210611","count":1},{"time":"20210617","count":2},{"time":"20210625","count":2},{"time":"20210705","count":2},{"time":"20210712","count":1},{"time":"20210720","count":1},{"time":"20210805","count":1},{"time":"20210813","count":1},{"time":"20210816","count":2},{"time":"20210823","count":1},{"time":"20210831","count":2},{"time":"20211021","count":1},{"time":"20211027","count":2},{"time":"20211028","count":1},{"time":"20211102","count":1},{"time":"20211111","count":1},{"time":"20211115","count":1},{"time":"20211118","count":1},{"time":"20211221","count":1},{"time":"20220110","count":1},{"time":"20220201","count":1},{"time":"20220202","count":1},{"time":"20220302","count":1},{"time":"20220307","count":1},{"time":"20220314","count":1},{"time":"20220318","count":1},{"time":"20220323","count":1},{"time":"20220325","count":1},{"time":"20220326","count":1},{"time":"20220412","count":1},{"time":"20220418","count":1},{"time":"20220419","count":1},{"time":"20220422","count":1},{"time":"20220425","count":1},{"time":"20220427","count":1},{"time":"20220428","count":4},{"time":"20220429","count":2},{"time":"20220503","count":5},{"time":"20220511","count":1},{"time":"20220512","count":2},{"time":"20220513","count":2},{"time":"20220516","count":1},{"time":"20220517","count":2},{"time":"20220518","count":5},{"time":"20220523","count":1},{"time":"20220531","count":1},{"time":"20220602","count":1},{"time":"20220613","count":1},{"time":"20220616","count":1},{"time":"20220628","count":1},{"time":"20220705","count":1},{"time":"20220708","count":2},{"time":"20220712","count":1},{"time":"20220713","count":1},{"time":"20220726","count":1},{"time":"20220809","count":1},{"time":"20220831","count":1},{"time":"20220916","count":2},{"time":"20220926","count":1},{"time":"20221018","count":1},{"time":"20221024","count":1},{"time":"20221025","count":1},{"time":"20221102","count":2},{"time":"20221104","count":1},{"time":"20221214","count":1},{"time":"20221227","count":1},{"time":"20230206","count":1},{"time":"20230208","count":1},{"time":"20230406","count":1},{"time":"20230419","count":1},{"time":"20230425","count":1},{"time":"20230502","count":1},{"time":"20230503","count":1},{"time":"20230525","count":1},{"time":"20230526","count":3},{"time":"20230626","count":1},{"time":"20230717","count":2},{"time":"20230811","count":1},{"time":"20230830","count":1},{"time":"20230831","count":2},{"time":"20230908","count":1},{"time":"20230925","count":1},{"time":"20231013","count":1},{"time":"20231016","count":1},{"time":"20231101","count":1},{"time":"20231103","count":1},{"time":"20231108","count":1},{"time":"20240105","count":1},{"time":"20240117","count":1},{"time":"20240126","count":1},{"time":"20240130","count":1},{"time":"20240301","count":1},{"time":"20240404","count":1},{"time":"20240415","count":1},{"time":"20240515","count":1},{"time":"20240516","count":1},{"time":"20240522","count":1},{"time":"20240620","count":1},{"time":"20240621","count":1},{"time":"20240624","count":1},{"time":"20240628","count":1},{"time":"20240718","count":1},{"time":"20240807","count":1},{"time":"20240812","count":1},{"time":"20240815","count":1},{"time":"20240906","count":1},{"time":"20240923","count":1},{"time":"20241105","count":1},{"time":"20241113","count":1},{"time":"20241127","count":1},{"time":"20250114","count":1},{"time":"20250117","count":2},{"time":"20250120","count":5},{"time":"20250121","count":1},{"time":"20250122","count":1},{"time":"20250213","count":1},{"time":"20250323","count":1},{"time":"20250418","count":1},{"time":"20250502","count":1},{"time":"20250513","count":1},{"time":"20250521","count":1},{"time":"20250529","count":1},{"time":"20250605","count":1},{"time":"20250617","count":1},{"time":"20250627","count":1},{"time":"20250702","count":1},{"time":"20250704","count":1},{"time":"20250707","count":1},{"time":"20250708","count":2},{"time":"20250724","count":1},{"time":"20250825","count":1},{"time":"20250903","count":1},{"time":"20250904","count":1},{"time":"20250909","count":2},{"time":"20250917","count":2},{"time":"20250919","count":1},{"time":"20250922","count":1},{"time":"20250925","count":1},{"time":"20251013","count":1},{"time":"20251021","count":1},{"time":"20251023","count":1},{"time":"20251027","count":1},{"time":"20251030","count":1},{"time":"20251105","count":1},{"time":"20251114","count":2},{"time":"20251224","count":1},{"time":"20251230","count":1}],"recentPublications":[{"pmid":"16915833","title":"Stability-indicating methods for the determination of disopyramide phosphate.","authors":"Salem MY, Ramadan NK, Moustafa AA, El-Bardicy MG","journal":"J AOAC Int","pubDate":"2006 Jul-Aug"},{"pmid":"16635993","title":"Increased AAI mode pacing threshold after termination of atrial fibrillation by acute administration of disopyramide phosphate.","authors":"Anzawa R, Ishikawa S, Tanaka Y, Okazaki F, Mochizuki S","journal":"Europace","pubDate":"2006 May"},{"pmid":"15976979","title":"Atrial pacing failure following termination of atrial fibrillation by acute administration of disopyramide phosphate.","authors":"Anzawa R, Ishikawa S, Tanaka Y, Okazaki F, Mochizuki S","journal":"J Interv Card Electrophysiol","pubDate":"2005 Jun"},{"pmid":"11225596","title":"Sinus node recovery time assessment by the overdrive suppression test employing an intravenous injection of disopyramide phosphate.","authors":"Ishikawa T, Sumita S, Kimura K, Kikuchi M, Kosuge M","journal":"Europace","pubDate":"2000 Jan"},{"pmid":"2109870","title":"[Effects of verapamil and disopyramide phosphate on the termination, reinduction and long-term prevention of paroxysmal supraventricular tachycardia].","authors":"Tsuchioka Y, Nakagawa H, Yamagata T, Sakura E, Hashimoto M","journal":"Kokyu To Junkan","pubDate":"1990 Mar"},{"pmid":"3444847","title":"In vitro study of gastrointestinal diffusion system using disopyramide phosphate.","authors":"Jedras Z, Janicki S","journal":"Pharmazie","pubDate":"1987 Dec"},{"pmid":"3103491","title":"A review of the effects of disopyramide phosphate on left ventricular function and the peripheral circulation.","authors":"Di Bianco R, Gottdiener JS, Singh SN, Fletcher RD","journal":"Angiology","pubDate":"1987 Feb"},{"pmid":"3089566","title":"Disopyramide phosphate effects on slow and depressed fast responses.","authors":"Schanne OF, Bkaily G, Dumais B, Boutin L","journal":"Can J Physiol Pharmacol","pubDate":"1986 Apr"},{"pmid":"3082173","title":"Long-term therapy with disopyramide phosphate: side effects and effectiveness.","authors":"Bauman JL, Gallastegui J, Strasberg B, Swiryn S, Hoff J","journal":"Am Heart J","pubDate":"1986 Apr"},{"pmid":"2419948","title":"[Clinical evaluation of the effectiveness and stability of action of sustained-release disopyramide phosphate by the Holter method].","authors":"de Lombera Romero F, Martínez-Osorio Corzan L, Seoane J, Franco JR","journal":"Rev Esp Cardiol","pubDate":"1985 Nov-Dec"}],"storageAndHandling":"","_drugWebsiteChecked":true,"participantFlowData":[],"_healthCanadaChecked":true,"companionDiagnostics":[],"faersSexDistribution":[{"term":2,"count":577},{"term":1,"count":277},{"term":0,"count":9}],"genericManufacturers":["DR REDDYS LABS SA","PFIZER","TEVA"],"_genericFilersChecked":true,"nonclinicalToxicology":"Carcinogenesis, Mutagenesis, Impairment of Fertility Eighteen months of disopyramide phosphate administration to rats, at oral doses up to 400 mg/kg/day (about 30 times the usual daily human dose of 600 mg/day, assuming a patient weight of at least 50 kg), revealed no evidence of carcinogenic potential. An evaluation of mutagenic potential by Ames test was negative. disopyramide phosphate, at doses up to 250 mg/kg/day, did not adversely affect fertility of rats.","structuredTrialResults":[],"genericManufacturerList":[],"faersSeriousnessBreakdown":[{"term":1,"count":519},{"term":2,"count":425}],"phase":"marketed","status":"approved","companyName":"Pfizer","companyId":"pfizer","modality":"Small molecule","firstApprovalDate":"1977","enrichmentLevel":5,"visitCount":17,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"pricingByCountry":[{"country_code":"Un","currency":"USD","price_amount":"486.00","price_per":"year","price_type":"NADAC","annual_cost_usd":null,"reimbursement_status":null},{"country_code":"UN","currency":"USD","price_amount":"486.00","price_per":"year","price_type":"NADAC","annual_cost_usd":null,"reimbursement_status":null},{"country_code":"UN","currency":"USD","price_amount":"486.00","price_per":"year","price_type":"NADAC","annual_cost_usd":null,"reimbursement_status":null},{"country_code":"UN","currency":"USD","price_amount":"486.00","price_per":"year","price_type":"NADAC","annual_cost_usd":null,"reimbursement_status":null},{"country_code":"UN","currency":"USD","price_amount":"486.00","price_per":"year","price_type":"NADAC","annual_cost_usd":null,"reimbursement_status":null}],"trialStats":{"total":1,"withResults":1},"validation":{"fieldsValidated":3,"lastValidatedAt":"2026-04-20T07:54:19.621555+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":false,"score":3}}